Introduction {#s1}
============

The neural crest is an embryonic progenitor cell population common to all vertebrates. These cells are highly migratory and give rise to tissues canonically derived from both ectoderm and mesoderm, including bone and cartilage of the head, peripheral neurons, and pigment cells. Neural crest specification begins during gastrulation with the expression of neural plate border specifiers. As development proceeds to the neurula stage, these transcription factors in turn regulate the expression of neural crest specifiers, which mark cells that will migrate and differentiate into neural crest derivatives ([@bib43]). Not all neural plate border cells are fated to become neural crest, raising the question of which signals regulate the decision between neural crest and other ectodermal derivatives.

In several cases the same signals that regulate neural plate border specification can later regulate neural crest specification. Reiterated Wnt signaling plays a role in neural crest development in chicks, frogs, zebrafish ([@bib15]; [@bib33]; [@bib26]; [@bib42]). Wnt acts early in neural crest development to regulate expression of the neural plate border genes *pax3* and *msx1*, as well as later to allow *pax3* and *zic1* to activate transcription of neural crest specifiers including *foxd3* and *slug* ([@bib26]; [@bib42]). BMP is also reported to play a reiterated role in neural crest development. In *Xenopus* attenuation of BMP signaling by Hairy2 upregulates neural plate border genes but inhibits neural crest genes ([@bib35]).

While much work has contributed to our knowledge of morphogens required for neural crest induction, less is known about the intracellular signals that are activated in response to these ligands. Fibroblast growth factor (FGF) is reported to play both a cell autonomous and non-cell autonomous role in neural crest induction, either by directly inducing neural crest gene expression or by inducing Wnt8 expression in the paraxial mesoderm ([@bib19]; [@bib56]; [@bib45]). FGFs can activate four major intracellular pathways: MAPK, AKT, PLCγ, and STAT ([@bib51]). Which of these are important during neural crest has not been systematically addressed, though several studies have shown that MAPK signaling acts downstream of FGF in early neural crest induction ([@bib45]; [@bib28]).

Akt, also referred to as protein kinase B, is a critical effector downstream of receptor tyrosine kinases. Classically studied for its oncogenic properties, Akt and its upstream activator PI3-kinase (PI3K) play an important role in cell survival and cell cycle progression. Akt also plays a role in the development of many tissues, canonically acting through negative regulation of FoxO transcription factors ([@bib1]). The Akt pathway has been particularly well-studied in the context of myogenic differentiation, where it induces myoblast fusion ([@bib20]). Akt also regulates β-catenin, promoting its transcriptional activity by both direct and indirect phosphorylation ([@bib13]).

In this study we took advantage of chemical screening in zebrafish to better understand pathways regulating neural crest development. We developed a heterogeneous neural crest cell culture system to screen for chemicals that specifically decrease expression of the neural crest marker *crestin:EGFP*. We found that caffeic acid phenethyl ester (CAPE) inhibits expression of *crestin* by reducing Sox10 activity. CAPE also disrupts neural crest migration and decreases formation of pigmented melanocytes. We found that CAPE inhibits FGF-stimulated PI3K/Akt signaling in vitro, and expression of constitutively active Akt1 suppresses the effects of CAPE on the neural crest in vivo. Reduction of Akt activity by constitutively active PTEN similarly decreases *crestin* expression. We have identified PI3K/Akt as a novel intracellular pathway required for neural crest differentiation through regulation of Sox10 activity.

Results {#s2}
=======

An in vitro screen for chemicals that decrease *crestin:EGFP* expression {#s2-1}
------------------------------------------------------------------------

To better understand the signals essential for neural crest development, we looked for small molecules that decreased expression of the neural crest reporter *crestin_1 kb:EGFP* (hereafter referred to as *crestin:EGFP*). The 1 kb *crestin* promoter fragment recapitulates endogenous *crestin* mRNA expression, thus marking the neural crest lineage in vivo ([@bib21]). We developed a neural crest culture protocol to facilitate rapid and automated chemical screening while maintaining this transient cell population in heterogeneous cultures ([Figure 1A,B](#fig1){ref-type="fig"}) ([@bib5]). This approach allowed us to distinguish broadly toxic chemicals from those with selective effects on the neural crest. *Crestin:EGFP; ubi:mCherry* transgenic zebrafish embryos were grown to the 5 somite stage (ss), mechanically homogenized, and plated on standard tissue culture-coated plastic in media optimized for neural crest growth and survival, containing fetal bovine serum (FBS), epidermal growth factor (EGF), fibroblast growth factor 2 (FGF2), and insulin ([@bib23]). Under these conditions, *crestin:EGFP*+ cells arose and proliferated, accounting for approximately 20% of total cells after 24 hr in culture ([Figure 1---figure supplement 1A--B](#fig1s1){ref-type="fig"}). These cells were highly proliferative and migratory, expressed key neural crest genes, and could differentiate into pigmented melanocytes in vivo ([Figure 1---figure supplement 1C--F](#fig1s1){ref-type="fig"} and [Video 1](#video1){ref-type="video"}).

![Chemical screening in zebrafish embryonic cell cultures identifies inhibitors of neural crest development.\
(**A**) CAPE decreases *crestin:EGFP*+ cells in culture while leaving *ubi:mCherry*+ cells unchanged. Scale bar: 100 μm. Characterization of cultured *crestin:EGFP*+ cells is shown in [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}. (**B**) Chemical screen design. Whole embryos were mechanically homogenized and plated on standard tissue culture coating in neural crest medium with chemicals. After 24 hr of culture, Hoechst 33342 was added to stain nuclei before imaging. (**C**) Screen hits were validated in the primary screen assay and tested for an effect on *crestin:EGFP* expression in vivo. (**D**) Structure of CAPE. (**E**) CAPE shows a greater than 10-fold selectivity for *crestin:EGFP*+ cells versus *ubi:mCherry*+ cells *in vitro*.\
10.7554/eLife.29145.004Figure 1---source data 1.*Ubi:mCherry* and *crestin:EGFP+* cell numbers in CAPE-treated cultures.](elife-29145-fig1){#fig1}

###### *Crestin:EGFP *time lapse in heterogeneous neural crest cultures.

10.7554/eLife.29145.009

We used this primary cell culture system to screen 3400 compounds at two concentrations, including bioactives libraries, FDA approved drugs, and Chembridge novel compounds. Chemical hits were identified based on toxicity and specificity cutoffs, taking into account both total cell number as determined by Hoechst staining of nuclei and *ubi:mCherry*+ cells representing a random population of cells ([Figure 1A,B](#fig1){ref-type="fig"}). All hits were verified by eye, resulting in a hit rate of 1.0--1.8%. Of 86 non-redundant, commercially available hit chemicals, 72 reproduced a specific, dose-dependent decrease in number of *crestin:EGFP*+ cells in culture ([Figure 1C](#fig1){ref-type="fig"}, [Table 1](#table1){ref-type="table"}). We next tested the effect of hit chemicals on *crestin:EGFP* transgenic zebrafish embryos treated at 2 ss (10.6 hpf), early in neural crest specification but after the neural plate border is established. Sixteen chemicals decreased *crestin:EGFP* in vivo, including CAPE, a natural product with multiple reported biological activities and targets ([Figure 1D--E](#fig1){ref-type="fig"}, [Table 1](#table1){ref-type="table"}).

10.7554/eLife.29145.010

###### In vitro validated screen hits.

Hits that also validated in vivo are bold.

  Compound                                                                                                                    Library        Target/category
  --------------------------------------------------------------------------------------------------------------------------- -------------- --------------------------------------------
  **CAPE**                                                                                                                    ICCB           NFkB/multiple
  raloxifene                                                                                                                  LOPAC          Estrogen receptor
  mianserin                                                                                                                   LOPAC          5-HT receptor antagonist
  GANT61                                                                                                                      LOPAC          Hedgehog
  MnTBAP                                                                                                                      ICCB           SOD mimetic
  loperamide                                                                                                                  FDA approved   Mu opiod receptor agonist
  latanoprost                                                                                                                 FDA approved   prostaglandin F2a analogue
  tetraethylthiuram disulfide                                                                                                 LOPAC          alcohol dehydrogenase
  dopamine                                                                                                                    LOPAC          dopamine receptor
  mycophenolate mofetil                                                                                                       LOPAC          IMPH
  genistein                                                                                                                   LOPAC          kinase inhibitor
  albendazole                                                                                                                 FDA approved   antihelminthic
  JFD00244                                                                                                                    LOPAC          sirt2 inhibitor
  perphenazine                                                                                                                FDA approved   5-HT receptor
  5-NOT                                                                                                                       FDA approved   5-HT agonist
  SKF95282                                                                                                                    LOPAC          histamine H2 receptor antagonist
  bicalutamide                                                                                                                FDA approved   anti-androgen
  **capsazepine**                                                                                                             LOPAC          sodium channels
  triflupromazine                                                                                                             LOPAC          monoamine transporters
  flubendazole                                                                                                                FDA approved   antihelminthic
  GDC-0941                                                                                                                    LOPAC          PI3K
  imatinib                                                                                                                    FDA approved   RTK inhibitor
  indatraline                                                                                                                 LOPAC          dopamine uptake inhibitor
  **MBCQ**                                                                                                                    ICCB           PDE5
  **MDL-28170**                                                                                                               ICCB           calpain inhibitor
  NS8593                                                                                                                      LOPAC          potassium channels
  **NU6027**                                                                                                                  LOPAC          ATR/CDK2 inhibitor
  PD180970                                                                                                                    LOPAC          RTK inhibitor
  PD173074                                                                                                                    LOPAC          src inhibitor
  PI-103                                                                                                                      LOPAC          PI3K
  rapamycin                                                                                                                   LOPAC          mTOR
  SB242084                                                                                                                    LOPAC          5-HT receptor antagonist
  **triptolide**                                                                                                              FDA approved   RNA pol II
  tyrphostin AG698                                                                                                            LOPAC          tyrosine kinase inhibitor
  wiskostatin                                                                                                                 LOPAC          actin
  PAC-1                                                                                                                       LOPAC          proapoptotic zinc chelator
  PD407824                                                                                                                    LOPAC          chk1 inhibitor
  PD173952                                                                                                                    LOPAC          src inhibitor
  sanguinarine                                                                                                                LOPAC          Na/K ATPase
  tyrphostin AG835                                                                                                            LOPAC          EGFR
  (-)-alpha-methylnorepinephrine                                                                                              LOPAC          sympathomimetic
  chloroquine                                                                                                                 LOPAC          antimalarial
  M-344                                                                                                                       LOPAC          HDAC inhibitor
  olmesartan medoxomil                                                                                                        FDA approved   angiotensin II receptor antagonist
  **1,10-phenanthroline**                                                                                                     LOPAC          chelator, MMP
  **2,3-dimethoxy-1,4-naphthoquinone**                                                                                        LOPAC          ROS
  amiloride                                                                                                                   ICCB           calcium channels
  fluvastatin                                                                                                                 FDA approved   HMG co-A reductase
  CHM-1                                                                                                                       LOPAC          antimitotic
  SAHA                                                                                                                        LOPAC          HDAC inhibitor
  **nimesulide**                                                                                                              LOPAC          COX-2
  mibefradil                                                                                                                  LOPAC          calcium channels
  KB-R7493                                                                                                                    LOPAC          sodium calcium exchanger
  LY165163                                                                                                                    LOPAC          5-HT receptor antagonist
  dequalinium                                                                                                                 LOPAC          potassium channels
  AM92016                                                                                                                     ICCB           potassium channels
  2-\[4-(1,3-benzodioxol-5-yl)−1H-pyrazol-1-yl\]-N-(2-ethyl-2H-1,2,3-triazol-4-yl)acetamide                                   Chembridge     predicted adenosine kinase
  N-(2-ethyl-2H-1,2,3-triazol-4-yl)−2-{4-\[3-(1H-pyrazol-1-yl)phenyl\]−1H-pyrazol-1-yl}acetamide                              Chembridge     predicted adenosine kinase
  2,2,6,6-tetramethyl-N-(1-methyl-3-phenylpropyl)−4-piperidinamine                                                            Chembridge     predicted vitamin D receptor
  N-\[(5-chloro-1H-indol-2-yl)methyl\]−2-(3-hydroxyphenyl)acetamide                                                           Chembridge     predicted TK(FLT3)
  5-(1H-indol-2-ylcarbonyl)−4,5,6,7-tetrahydrothieno\[3,2 c\]pyridine                                                         Chembridge     predicted TK(FLT3)
  1-acetyl-4-{4-\[1-(2-fluorophenyl)−1H-pyrazol-4-yl\]pyrimidin-2-yl}−1,4-diazepane                                           Chembridge     predicted JNK
  **4-(4-butyl-1H-1,2,3-triazol-1-yl)−1-{\[(1S\*,4S\*)−3,3-dimethyl-2-methylenebicyclo\[2.2.1\]hept-1-yl\]carbonyl}piperi**   Chembridge     predicted liver X receptor
  **1-(3-methylbenzyl)−4-thieno\[2,3-d\]pyrimidin-4-yl-2-piperazinone**                                                       Chembridge     predicted TK(EGFR, PDGFR, CSFR1); PKC; PKA
  **1-(2-methoxyphenyl)−2,2-dimethyl-4-(4-methylpentanoyl)piperazine**                                                        Chembridge     predicted androgen receptor
  **5,6-dimethyl-2-\[4-({methyl\[(2-methylpyridin-4-yl)methyl\]amino}methyl)phenyl\]pyrimidin-4(3 hr)-one**                   Chembridge     predicted estrogen receptor
  **N-\[1-(1,5-dimethyl-1H-pyrazol-4-yl)ethyl\]thieno\[2,3-d\]pyrimidin-4-amine**                                             Chembridge     predicted EGFR
  N-(1-cyclohexyl-1H-pyrazol-5-yl)−2-\[3-(2-thienyl)−1H-pyrazol-1-yl\]acetamide                                               Chembridge     predicted VEGFR2, EGF/KDR
  **2-\[1-(3-isobutyl-1,2,4-oxadiazol-5-yl)−2-methylbutyl\]−1-isoindolinone**                                                 Chembridge     predicted RAR(gamma)
  1-propyl-N-{1-\[4-(1H-pyrazol-1-yl)phenyl\]piperidin-4-yl}piperidin-4-amine                                                 Chembridge     predicted estrogen receptor
  **5-\[5-methyl-4-(1-methyl-1H-pyrazol-4-yl)pyrimidin-2-yl\]−4,5,6,7-tetrahydrothieno\[3,2 c\]pyridine**                     Chembridge     predicted TK(VEGFR, KDR, FLK1)
  **2-\[5-(2,6-dimethylphenyl)−1H-indazol-1-yl\]-N-(1,3-dimethyl-1H-pyrazol-5-yl)acetamide**                                  Chembridge     predicted TK(PDGFR, EGFR, FGFR)

CAPE disrupts neural crest gene expression in vivo by reducing Sox10 activity {#s2-2}
-----------------------------------------------------------------------------

Embryos treated with 10 μM CAPE at 2 ss showed a consistent and dramatic reduction in *crestin:EGFP* expression ([Figure 2A](#fig2){ref-type="fig"}). We saw a similar effect using the minimal 296 base pair *crestin* promoter (*crestin_296bp:EGFP*) ([Figure 2---figure supplement 1A](#fig2s1){ref-type="fig"}). To determine whether CAPE affects *crestin:EGFP* during or after neural crest specification, we conducted time lapse microscopy of *crestin:EGFP* transgenic embryos. In treated embryos, *crestin:EGFP* arose at a severely reduced level, and most *crestin:EGFP*+ cells that did emerge quickly disappeared, indicating that they had either died or turned off *crestin:EGFP* expression ([Videos 2](#video2){ref-type="video"} and [3](#video3){ref-type="video"}). Time course experiments confirmed that CAPE acts quickly and early in neural crest development. As determined by whole mount in situ hybridization (ISH), *crestin* expression was decreased after two hours of CAPE treatment, and CAPE had no effect on *crestin* expression in embryos treated at 15 ss or later ([Figure 2---figure supplement 1B--C](#fig2s1){ref-type="fig"}) .

![CAPE decreases neural crest gene expression.\
(**A**) CAPE dramatically reduces *crestin:EGFP* expression at 26 hpf. [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"} shows the response of a smaller (396 bp) *crestin* promoter fragment to CAPE and the timing of *crestin* response to CAPE. (**B**) CAPE decreases neural crest gene expression as determined by whole mount in situ hybridization (ISH) at 15--17 ss. Expression of some genes is decreased ubiquitously while others are only altered in specific anatomic locations (arrows). Images are representative of at least two independent experiments. (**C**) Scoring of ISH in (**B**). (**D**) CAPE reduces expression of pigment cell genes at 24 hpf. (**E**) FPKM values from RNA-sequencing of *sox10:Kaede*+ cells confirmed decreases in neural crest genes, though to a lesser extent than by ISH. Cells were sorted from control or CAPE-treated embryos at 17 ss. [Figure 2---figure supplement 2](#fig2s2){ref-type="fig"} shows neural crest genes with no significant change by ISH. [Figure 2---figure supplement 3](#fig2s3){ref-type="fig"} shows that a change in cell number does not account for neural crest gene expression changes. [Figure 2---figure supplement 4](#fig2s4){ref-type="fig"} shows other gene expression changes in neural crest cells. \*p\<0.001, \*\*p\<0.0001, chi-square test.\
10.7554/eLife.29145.016Figure 2---source data 1.Expression of neural crest genes by ISH in CAPE-treated embryos.](elife-29145-fig2){#fig2}

###### C*restin:EGFP* expression in DMSO-treated zebrafish embryos.

Embryos were treated at 2 ss and mounted for imaging at 10 ss. Embryos were imaged for 16.25 hr, and images were collected every 9 min.

10.7554/eLife.29145.021

###### C*restin:EGFP* expression in CAPE-treated (10 μM) zebrafish embryos.

Embryos were treated at 2 ss and mounted for imaging at 10 ss. Embryos were imaged for 16.25 hr, and images were collected every 9 min.

10.7554/eLife.29145.022

We further analyzed the effect of CAPE on neural crest gene expression by ISH. Embryos were treated with CAPE at 2 ss and fixed at 15--17 ss for analysis. We found a decrease in expression of *crestin*, *sox10*, *pax7a*, *dlx2a*, and the Ap-2α target gene *inka1a* ([Figure 2B,C](#fig2){ref-type="fig"}). These genes are expressed in both premigratory and migratory neural crest. We observed little to no change in the levels of *nr2f2*, *msxb*, *pax3a*, *ets1*, *ap2a*, *ap2c*, *snai1b*, dlx5a, and *foxd3* ([Figure 2---figure supplement 2A,B](#fig2s2){ref-type="fig"}). In addition to being expressed in the premigratory and migratory neural crest, a subset of these genes are expressed earlier in development at the neural plate border (*msxb*, *pax3a*, *dlx5a*). Our data indicate that neural crest-like cells are present in CAPE-treated embryos but exhibit abnormal gene expression, particularly for genes expressed after the neural plate border is established. Later in development, at 24 hpf, CAPE treatment caused a dramatic decrease in pigment cell-specific gene expression, including *mitfa* and its target gene *dct*, which mark melanoblasts, and *fms*, which marks xanthophore precursors ([Figure 2D](#fig2){ref-type="fig"}).

To confirm that changes in neural crest gene expression were not the result of reduced cell number, we evaluated proliferation and cell death in CAPE-treated embryos. After 6 hr of treatment, a time point at which neural crest gene expression is decreased by CAPE, no change in proliferation was observed in *sox10:GFP*+ cells, as determined by phospho-histone H3 staining ([Figure 2---figure supplement 3A,B](#fig2s3){ref-type="fig"}). To evaluate cell death, we used whole mount TUNEL staining combined with *crestin* ISH. We found a slightly increased number of overall TUNEL positive cells in embryos treated with 10 μM CAPE for 6 hr, but these cells were not present in the region of *crestin* expression, and the magnitude of increased cell death does not explain the differences in *crestin* expression ([Figure 2---figure supplement 3C,D](#fig2s3){ref-type="fig"}). After 19 hr of treatment, 10 μM CAPE increased cell death broadly throughout the embryo, most dramatically in the eye and tail, while 5 μM CAPE had no effect on cell death, even as late as 48 hpf ([Figure 2---figure supplement 3E,F](#fig2s3){ref-type="fig"}). These data indicate that increased cell death or reduced proliferation do not contribute to the early effects of CAPE on neural crest gene expression. The observed deficiency in pigment cell gene expression is also not explained by increased cell death, since this deficiency was observed with 5 μM CAPE treatment.

To confirm CAPE's effect on neural crest gene expression and identify potential mechanisms of action, we conducted RNA-seq on sorted *sox10:Kaede*+ cells from control and CAPE-treated embryos at 17 ss. This data confirmed that neural crest gene expression is decreased in cells from CAPE-treated embryos, though to a lesser extent than observed in ISH experiments ([Figure 2E](#fig2){ref-type="fig"}). Some genes including *pax3a* and *nr2f2* appeared unchanged by in situ but were downregulated in RNA-seq data ([Figure 2---figure supplement 2C](#fig2s2){ref-type="fig"}). *Sox10:Kaede* is more highly expressed in the cranial than trunk neural crest and is also highly expressed in the otic vesicle, potentially explaining the discrepancies between RNA-seq and ISH results. Consistent with ISH at 24 hpf, CAPE decreased expression of melanocyte-specific genes including *mitfa*, *ednrba*, and *tyr* ([Figure 2E](#fig2){ref-type="fig"}). Ingenuity Pathway Analysis (Qiagen) pointed to an increase in inflammatory signaling and changes in levels of morphogens such as Wnts, BMPs, and FGFs with CAPE treatment ([Figure 2---figure supplement 4](#fig2s4){ref-type="fig"}). These results suggest that CAPE's mechanism of action involves cell-cell signaling at the level of secreted ligand expression.

To better understand the mechanism by which CAPE leads to changes in gene expression, we conducted ATAC-seq (Assay for Transposase-Accessible Chromatin) in *sox10:Kaede*+ cells isolated from control and CAPE-treated embryos ([@bib3]). We observed a reduction in chromatin accessibility specifically at the *mitfa* promoter with CAPE treatment ([Figure 3A](#fig3){ref-type="fig"}). Changes in *mitfa* expression and chromatin accessibility could be downstream of Sox10, as Sox10 is known to bind to the promoter of *mitfa* and regulate its expression ([@bib12]). Indeed, ChIP-seq in a zebrafish melanoma cell line (zcrest 1) showed strong Sox10 binding at the *mitfa* promoter ([Figure 3A](#fig3){ref-type="fig"}) ([@bib21]). Other Sox10-bound genes including *crestin* did not show a reduction in chromatin accessibility even though their expression was decreased ([Figure 3B](#fig3){ref-type="fig"}). Therefore chromatin closing is likely not the primary mechanism by which CAPE decreases gene expression, but we used the ATAC-seq dataset to identify transcription factors of potential importance to CAPE's mechanism.

![CAPE reduces Sox10 activity.\
(**A**) ATAC-seq was conducted on *sox10:Kaede*+ cells from DMSO- or CAPE-treated embryos at two stages. CAPE reduces chromatin accessibility at the *mitfa* promoter in *sox10:Kaede*+ cells, and Sox10 binds the *mitfa* promoter in a zebrafish tumor cell line. (**B**) *Crestin* binds Sox10 but does not show a change in chromatin accessibility with CAPE treatment. Bar indicates region of *crestin* sequence similarity (chr4:41,270,000). (**C**) HOMER analysis of 20 ss ATAC-seq peaks revealed an enrichment for Sox and MITF motifs when comparing unique peaks in DMSO-treated embryos (% target) to all peaks in CAPE-treated embryos (% background). (**D**) CAPE (5 μM) prevents *sox10* RNA (30 pg) from increasing *crestin:EGFP* expression. (**E**) Quantification of experiment shown in (**D**). Sum of three clutches from two independent experiments is shown. [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"} shows that *tfap2c* RNA increases *crestin:EGFP* expression in both DMSO- and CAPE-treated embryos, and that the number of *sox10:Kaede*+ cells does not change with CAPE treatment.\
10.7554/eLife.29145.025Figure 3---source data 1.Scoring of *crestin:EGFP* expression in *sox10*-injected and CAPE-treated embryos.](elife-29145-fig3){#fig3}

To identify transcription factors that could mediate CAPE's effects on gene expression in a genome-wide unbiased manner, we used Hypergeometric Optimization of Motif EnRichment (HOMER) ([@bib18]). Of 81,140 total ATAC peaks, we identified 585 peaks (0.7%) unique to the DMSO control sample as compared to the CAPE-treated sample. We used these peak sequences as input to HOMER, with all peak sequences in the CAPE-treated sample as background. The most enriched motifs were those of Sox transcription factors, including Sox10, and MITF ([Figure 3C](#fig3){ref-type="fig"}). To determine whether CAPE affects Sox10 transcriptional activity, we overexpressed *sox10* in zebrafish embryos by RNA microinjection. While *sox10* injection increased *crestin:EGFP* expression in untreated embryos, it had no effect on *crestin:EGFP* expression in CAPE-treated embryos, indicating that CAPE reduces Sox10 activity ([Figure 3D--E](#fig3){ref-type="fig"}). Reduced expression of *crestin:EGFP* in CAPE-treated embryos was not due to a reduction in *sox10*-expressing cells, as the percentage of *sox10:Kaede*+ cells was identical in treated and control embryos ([Figure 3---figure supplement 1C](#fig3s1){ref-type="fig"}). In contrast to *sox10*, injection of *tfap2c* RNA increased *crestin:EGFP* in both control and CAPE-treated embryos, though its effect was subtle in both cases ([Figure 3---figure supplement 1A,B](#fig3s1){ref-type="fig"}). These data support a role for Sox10 in mediating the transcriptional effects of CAPE.

CAPE inhibits neural crest migration and pigment cell differentiation in vivo {#s2-3}
-----------------------------------------------------------------------------

We found that neural crest migration is also disrupted by CAPE. While *crestin:EGFP* is dramatically reduced upon CAPE treatment, *sox10:GFP* intensity is indistinguishable between control and treated embryos. This may be due to the strength of the *sox10* promoter or persistence of stable GFP. *Sox10:GFP* transgenic embryos allowed us to follow neural crest cells after CAPE treatment. These cells failed to reach the ventral half of the trunk in CAPE-treated embryos ([Figure 4A](#fig4){ref-type="fig"}, [Videos 4](#video4){ref-type="video"} and [5](#video5){ref-type="video"}). The cells remained rounded instead of extending projections and elongating ventrally, as was observed in control embryos ([Videos 4](#video4){ref-type="video"} and [5](#video5){ref-type="video"}). At 2 days post fertilization (dpf), pigmentation in CAPE-treated embryos was dramatically reduced, indicating that CAPE interferes with the production of differentiated melanocytes ([Figure 4B,C](#fig4){ref-type="fig"}). A migration defect was also apparent in the increased fraction of dorsal melanocytes at 2 dpf ([Figure 4D](#fig4){ref-type="fig"}). We found that CAPE's effect on neural crest migration co-occurred with decreased *mitfa:GFP* expression. A melanocyte migration defect was still evident when embryos were treated with CAPE at 15 ss ([Figure 4D](#fig4){ref-type="fig"}). Therefore the melanocyte migration defect induced by CAPE may be downstream of decreased *mitfa* expression.

![CAPE inhibits neural crest migration and pigment cell differentiation.\
Embryos were treated at 2 ss unless otherwise indicated. (**A**) *Sox10:Kaede*+ cells in the trunk of zebrafish embryos are more dorsally located at 24 hpf. Dotted line indicates top of yolk sac extension. CAPE-treated embryos were allowed to develop for 4 hr longer than control embryos for stage matching. Numbers indicate fraction of embryos for which images are representative. Some DMSO control embryos showed a pattern similar to 5 μM CAPE. Similar results were observed in three independent experiments. (**B**) Morphology and pigmentation of CAPE-treated embryos at 2 dpf. Treated embryos showed reduced pigmentation and defects such as pericardial edema and a curved tail. (**C**) Melanocyte counts corresponding to (**B**). Trunk melanocytes were counted from the yolk sac extension to the end of the tail. Error bars represent standard deviation of 10 embryos from two independent experiments. (**D**) CAPE increases the fraction of dorsal melanocytes at 2 dpf. Melanocytes were counted as in (**C**). Embryonic stage at drug treatment is indicated. \*p\<0.05, \*\*p\<0.0005, unpaired t-test. [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"} shows the effect of CAPE on xanthophores and iridophores at 3 dpf. [Figure 4---figure supplement 2](#fig4s2){ref-type="fig"} shows the effect of CAPE on otic vesicle development.\
10.7554/eLife.29145.031Figure 4---source data 1.Melanocyte numbers in CAPE-treated embryos.\
10.7554/eLife.29145.032Figure 4---source data 2.Fraction dorsal melanocytes in CAPE-treated embryos.](elife-29145-fig4){#fig4}

###### Neural crest migration in DMSO-treated zebrafish embryos.

*Sox10:GFP* transgenic embryos were treated at 2 ss and mounted for imaging at 15 ss. Embryos were imaged for 12 hr, and images were collected every 10 min.

10.7554/eLife.29145.035

###### Neural crest migration in CAPE-treated (10 μM) zebrafish embryos.

*Sox10:GFP* transgenic embryos were treated at 2 ss and mounted for imaging at 15 ss. Embryos were imaged for 12 hr, and images were collected every 10 min.

10.7554/eLife.29145.036

We further evaluated the effect of CAPE on xanthophores and iridophores at 3 dpf. We found that CAPE reduces iridophore number, size, and pigmentation, though this effect was not as dramatic as the effect of CAPE on melanocytes ([Figure 4---figure supplement 1A,B](#fig4s1){ref-type="fig"}). As for melanocytes, we saw an increase in the fraction of dorsal iridophores, but this effect was again less pronounced than the melanocyte position defect ([Figure 2D](#fig2){ref-type="fig"}, [Figure 4---figure supplement 1C](#fig4s1){ref-type="fig"}). Though we saw reduced *fms* expression at 24 hpf, we found that by 3 dpf, xanthophores had recovered. CAPE-treated embryos in fact showed more intense yellow pigmentation that control embryos, particularly in the head ([Figure 4---figure supplement 1A](#fig4s1){ref-type="fig"}). These data indicate that CAPE treatment has selective effects on different pigment cell lineages.

Since Sox10 plays an important role in otic placode development, we evaluated the effect of CAPE on the otic vesicle at 24 and 48 hpf ([@bib11]). We found that CAPE causes a subtle defect in otic vesicle shape at 24 hpf. At 48 hpf, CAPE-treated embryos lack semicircular canal projections and have more closely spaced otoliths ([Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}). These defects are consistent with a reduction in Sox10 activity, since they have been observed in *sox10* mutants ([@bib11]).

Inhibition of Akt signaling contributes to CAPE-induced defects in neural crest development {#s2-4}
-------------------------------------------------------------------------------------------

CAPE has previously been reported to inhibit Akt signaling in melanoma cell lines by inhibition of PI3K activity ([@bib38]). In addition to CAPE, we identified the PI3K inhibitors PI-103 and GDC-0941 as strong hits in our screen and confirmed that they specifically reduce *crestin:EGFP*+ cell number in a dose-responsive manner ([Figure 5---figure supplement 1A](#fig5s1){ref-type="fig"}). To determine whether inhibition of Akt signaling might contribute to the effects of CAPE on the zebrafish neural crest, we overexpressed constitutively active, membrane-targeted human Akt1 (myr-Akt1) in zebrafish embryos by RNA microinjection. Injection of myr-Akt1 increased Akt phosphorylation independent of CAPE treatment and rescued *crestin* expression in CAPE-treated embryos ([Figure 5A--C](#fig5){ref-type="fig"}). Myr-Akt1 injection also partially rescued both melanocyte number and melanocyte migration at 2 dpf ([Figure 5D--F](#fig5){ref-type="fig"}). Defects such as pericardial edema and curved tail showed a slight but consistent decrease with myr-Akt1 injection ([Figure 5---figure supplement 1B](#fig5s1){ref-type="fig"}). Overall these data indicate that inhibition of Akt signaling contributes to CAPE's effects on both gene expression and migration of neural crest cells.

![Myr-Akt1 rescues neural crest defects caused by CAPE.\
(**A**) Injection of myr-Akt1 RNA results in high phospho-Akt in heterogeneous neural crest cultures regardless of CAPE treatment. The same result was observed in four independent experiments. (**B**) Scoring system for *crestin* in situ hybridization. (**C**) Myr-Akt1 injection increases *crestin* expression in CAPE-treated embryos. Each point represents the average score of embryos from a single clutch (23--66 embryos per clutch). Three independent experiments are shown. (**D**) Morphology and pigmentation of CAPE-treated and injected embryos at 2 dpf. Images are representative of three independent experiments. (**E**) Myr-Akt1 increases melanocyte number in CAPE-treated embryos. Trunk melanocytes were counted as in [Figure 4](#fig4){ref-type="fig"}. Each point represents one embryo from the same clutch; bars indicate mean. (**F**) Myr-Akt1 reduces the fraction of dorsal melanocytes in CAPE-treated embryos. \*p\<0.05, \*\*p\<0.005, (**C**) paired t-test, (**E--F**) unpaired t-test. [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"} shows the effect of PI3K inhibitors on *crestin:EGFP* expression in vitro and the effect of myr-Akt1 on CAPE-induced embryonic defects.\
10.7554/eLife.29145.039Figure 5---source data 1.Scoring of *crestin* expression by ISH in CAPE-treated and myr-Akt1-injected embryos.\
10.7554/eLife.29145.040Figure 5---source data 2.Melanocyte numbers in CAPE-treated and myr-Akt1-injected embryos.\
10.7554/eLife.29145.041Figure 5---source data 3.Melanocyte numbers in CAPE-treated and myr-Akt1-injected embryos.](elife-29145-fig5){#fig5}

To more precisely elucidate the mechanism of Akt inhibition by CAPE, we returned to the in vitro culture system we used for chemical screening. This system provides an opportunity to control chemical cues received by prospective neural crest cells. In addition to FBS, which contains unknown factors required for neural crest induction in vitro, two growth factors in the culture medium promoted neural crest induction: FGF2 and insulin ([Figure 6A,B](#fig6){ref-type="fig"}). We studied two pathways known to be activated downstream of these factors: PI3K/Akt and Mek/Erk. We found that while insulin primarily activated Akt, FGF primarily activated Erk ([Figure 6C,D](#fig6){ref-type="fig"}).

![CAPE inhibits FGF-stimulated Akt activation in vitro.\
Embryos were plated in neural crest medium and cultured for 2 hr for western blotting. (**A**) Heterogeneous neural crest cultures after 24 hr in neural crest medium with or without FGF and insulin. Scale bar: 100 μm. Images are representative of three independent experiments. (**B**) Quantification of *crestin:EGFP*+ cells for (**A**). Number of cells was determined by thresholding and normalized to *ubi:mCherry* fluorescence representing total cell number. Mean and standard deviation of at least 4 wells is shown. (**C**) Ratio of phosphorylated to total Akt. Each point represents an independent experiment corresponding to color. Samples were normalized within an experiment so that p-Akt to Akt ratio with FGF and insulin but without CAPE (condition 5) had a value of 1. Insulin but not FGF stimulation leads to Akt phosphorylation. CAPE inhibits Akt only in FGF-stimulated cells. (**D**) Ratio of phosphorylated to total Erk. Values were normalized as in (**C**). FGF but not insulin stimulation leads to Erk phosphorylation. ‡ no signal detected \*p\<0.05, \*\*p\<0.005, \*\*\*p\<0.0005, paired t-test. [Figure 6---figure supplement 1](#fig6s1){ref-type="fig"} shows a model for CAPE's mechanism of action based on the effects of a Mek inhibitor (CI-1040) and a PI3K inhibitor (PI-103) on Akt and Erk phosphorylation. [Figure 6---figure supplement 2](#fig6s2){ref-type="fig"} shows the effect of RTK inhibitors on *crestin* expression in vivo.\
10.7554/eLife.29145.048Figure 6---source data 1.Number of *crestin:EGFP+* cells per total *ubi:mCherry* fluorescence.\
10.7554/eLife.29145.049Figure 6---source data 2.Quantification of p-Erk/Erk and p-Akt /Akt ratios by western blot and densitometry.](elife-29145-fig6){#fig6}

Surprisingly, we found that CAPE inhibited Akt phosphorylation only in the presence of FGF, even though FGF itself did not promote Akt activation ([Figure 6C](#fig6){ref-type="fig"}, [Figure 6---figure supplement 1A](#fig6s1){ref-type="fig"}). This was not true for the PI3K inhibitor PI-103 that prevented Akt phosphorylation regardless of FGF stimulation ([Figure 6---figure supplement 1C](#fig6s1){ref-type="fig"}). We hypothesized that the apparent lack of Akt stimulation by FGF could be explained by Akt inhibition by another pathway. Addition of a Mek inhibitor to the cultures resulted in a dramatic increase in p-Akt, leading us to postulate that Mek/Erk negatively regulates PI3K/Akt ([Figure 6---figure supplement 1A](#fig6s1){ref-type="fig"}, last two lanes). In the context of Mek inhibition, we saw that FGF activated Akt to a similar extent as insulin ([Figure 6---figure supplement 1A](#fig6s1){ref-type="fig"}, first three lanes). FGF treatment enhanced the ability of Mek inhibition to stimulate p-Akt ([Figure 6---figure supplement 1A](#fig6s1){ref-type="fig"}, compare lanes 4 and 6). Mek inhibition also blunted the ability of CAPE to reduce p-Akt ([Figure 6---figure supplement 1B](#fig6s1){ref-type="fig"}, compare lanes 2 and 6). Finally, the induction of p-Akt by Mek inhibition was PI3K-dependent, since it was blocked by a PI3K inhibitor ([Figure 6---figure supplement 1B](#fig6s1){ref-type="fig"}, lanes 1--4). These observations led us to formulate a model in which FGF modulates Akt activation through a mechanism distinct from insulin-stimulated Akt activation and sensitive to CAPE activity ([Figure 6---figure supplement 1D](#fig6s1){ref-type="fig"}). Since the phosphorylation of membrane-targeted Akt1 (myr-Akt1) is not affected by CAPE, CAPE acts upstream of Akt membrane recruitment by PIP3 ([Figure 5A](#fig5){ref-type="fig"}). CAPE could function through inhibition of PI3K or activation of Pten, a negative regulator of PIP3. We ruled out the latter hypothesis, since CAPE had the same effect on *crestin* expression in wild type or *ptena-/-;ptenb-/-* embryos ([Figure 6---figure supplement 1E](#fig6s1){ref-type="fig"}).

While FGF2 and insulin were used to induce neural crest in culture, we asked what growth factors regulate neural crest development in vivo. Many kinase inhibitors scored as hits in our initial screen, including two chemicals from the Chembridge KINAcore library that were generated as structural analogs to receptor tyrosine kinase (RTK) inhibitors. These two chemicals also decreased *crestin* expression in vivo, while EGFR, FGFR, insulin-like growth factor receptor, and insulin receptor inhibitors had no effect when added at 2 ss ([Figure 6---figure supplement 2](#fig6s2){ref-type="fig"}). Importantly we tested SU5402, an FGFR inhibitor with demonstrated activity in zebrafish embryos ([@bib32]). This data suggests that a growth factor other than FGF activates Akt in neural crest cells in vivo.

Akt signaling regulates neural crest gene expression in vivo {#s2-5}
------------------------------------------------------------

To confirm that Akt activation plays a role in zebrafish neural crest development, we expressed constitutively active human PTEN-mCherry fusion (PTEN S370A, S380A, T382A, T383A, S385A or PTEN QMA) in *crestin:EGFP* transgenic zebrafish embryos ([@bib17]; [@bib46]). After sorting embryos based on mCherry fluorescence at 24 hpf, we found that PTEN QMA-mCherry decreases both phospho-Akt and *crestin:EGFP* expression ([Figure 7A--C](#fig7){ref-type="fig"}). We found a similar decrease in *crestin* expression by ISH ([Figure 7D](#fig7){ref-type="fig"}). The PI3K inhibitor LY294002 also decreased *crestin:EGFP* expression in vivo in a dose responsive manner ([Figure 7E](#fig7){ref-type="fig"}). Similar to CAPE treatment, we found that co-injection of PTEN QMA prevented *sox10* from stimulating *crestin:EGFP* expression ([Figure 7F--G](#fig7){ref-type="fig"}). These data support a role for Akt activation in Sox10-dependent neural crest gene transcription.

![Akt signaling regulates neural crest gene expression in vivo.\
(**A**) PTEN QMA-mCherry (300 pg) reduces phospho-Akt level in whole embryos. (**B**) Morphology, PTEN QMA-mCherry expression, and *crestin:EGFP* expression of PTEN QMA-mCherry injected embryos. Scoring system for *crestin:EGFP* levels is indicated. (**C**) Quantification based on scoring in (**B**). Each point represents a single clutch (5--53 embryos per condition), and mean is indicated. One clutch generated less than 5 PTEN QMA-mCherry low embryos and is not shown. \*p\<0.01, Student's t-test (**D**) PTEN QMA-mCherry decreases *crestin* expression by ISH. Embryos were scored as in [Figure 5B](#fig5){ref-type="fig"}. Average score normalized to uninjected control is indicated. Error bars represent SEM of four clutches (7--28 embryos per condition) from three independent experiments. One clutch was excluded because of abnormally low staining in both control and injected embryos. (**E**) The PI3K inhibitor LY294002 decreases *crestin:EGFP* expression. Points indicate the average of two independent experiments. (**F**) PTEN QMA-mCherry prevents Sox10 from stimulating *crestin:EGFP* expression. Representative embryos from the same clutch are shown. (**G**) Three clutches (8--19 embryos per condition) from two independent experiments were scored as in (**B**).\
10.7554/eLife.29145.053Figure 7---source data 1.Scoring of *crestin:EGFP *expression in PTEN QMA-mCherry-injected embryos.\
10.7554/eLife.29145.054Figure 7---source data 2.Scoring of *crestin *expression by ISH in PTEN QMA-injected embryos.\
10.7554/eLife.29145.055Figure 7---source data 3.Scoring of *crestin:EGFP *expression in LY294002-treated embryos.\
10.7554/eLife.29145.056Figure 7---source data 4.Scoring of *crestin:EGFP *in *sox10*- and PTEN-injected embryos.](elife-29145-fig7){#fig7}

Discussion {#s3}
==========

Neural plate border cells have the capacity to form both neural and non-neural ectodermal derivatives in addition to neural crest cells. While neural plate border specifiers direct expression of neural crest specifiers, the role of additional cues in promoting neural crest specifier expression and activity are poorly characterized. In this study, we used in vitro chemical screening to establish a key role for PI3K/Akt signaling in neural crest development.

Chemical screening in zebrafish provided several advantages over traditional approaches. First, we used an in vitro screening system that facilitated automation, minimized the time-dependency of neural crest gene expression, and maintained cell type heterogeneity. Second, we treated zebrafish embryos at a developmental time point when the neural plate border is already established. Third, we avoided a common limitation of genetic studies in which isoform redundancy masks a phenotype in loss-of-function studies.

We found that CAPE treatment and subsequent inhibition of Akt signaling decreased expression of neural crest genes and led to a failure of neural crest cells to migrate. CAPE also reduced the number of pigmented melanocytes in zebrafish embryos. CAPE-treated embryos exhibited severe defects or death after more than two days of development, confounding analysis of other neural crest derivatives such as peripheral neurons and cartilage. Though CAPE has many reported activities, we found that inhibition of Akt signaling was relevant for its effects on the neural crest. In CAPE-treated embryos, constitutively active Akt1 rescued *crestin* expression, melanocyte number, and melanocyte migration.

We further used neural crest selective cell cultures to investigate CAPE's mechanism of action in the context of particular growth factor stimulation. Although FGF itself did not appear to stimulate Akt phosphorylation, FGF was required for the activity of CAPE. We hypothesized that FGF could activate both PI3K/Akt and Mek/Erk pathways, but that Mek/Erk activation leads to PI3K/Akt cross-inhibition, as has been previously published ([@bib57]; [@bib50]; [@bib58]; [@bib31]). This hypothesis was supported by a dramatic increase in Akt phosphorylation upon Mek inhibition ([Figure 6---figure supplement 1A](#fig6s1){ref-type="fig"}). We formulated a model in which FGF modulates Akt activation depending on the level of Mek/Erk activity ([Figure 6---figure supplement 1D](#fig6s1){ref-type="fig"}). FGF stimulation acts like a pendulum that can swing between PI3K/Akt activation or Mek/Erk activation. Under baseline conditions, FGF stimulation has no net effect on Akt phosphorylation, since FGF both activates Akt and inhibits Akt through Mek/Erk. When a Mek inhibitor is present, FGF stimulates Akt activation. When CAPE is present, FGF-stimulated Akt activation is inhibited, and the negative effect of Mek/Erk on Akt is dominant, leading to decreased Akt phosphorylation. Consistent with this model, the effect of CAPE on Akt phosphorylation was blunted upon Mek inhibition.

The direct target of CAPE is yet to be determined, but CAPE likely acts upstream of PI3K. CAPE does not inhibit phosphorylation of membrane-targeted Akt1, so it acts upstream of PIP3, which recruits Akt to the cell membrane ([Figure 5A](#fig5){ref-type="fig"}). Hence CAPE could either activate Pten or inhibit PI3K. We ruled out Pten activation by showing that CAPE has an identical effect on *crestin* expression in wild type or *pten* null embryos ([Figure 6---figure supplement 1E](#fig6s1){ref-type="fig"}).

Several lines of evidence pointed to Sox10 as a downstream transcription factor affected by CAPE. We found that CAPE treatment decreased chromatin accessibility at Sox10 binding sites, including the promoter of *mitfa*. Furthermore, CAPE's effects on neural crest gene expression mirror that of the zebrafish *colourless* mutant in which *sox10* is disrupted: s*ox10* expression is slightly reduced, while expression of *mitfa* and its target genes are dramatically reduced ([@bib10]). The dramatic reduction in both *crestin* and *mitfa* expression in CAPE-treated embryos is consistent with a reduction in Sox10 activity. While Mitf expression depends on both Pax3 and Sox10, only Sox10 binding sites are essential for *crestin* expression, while Pax3 binding sites are dispensable ([@bib37]; [@bib12]; [@bib21]). CAPE-treated embryos also show an otic vesicle defect that is similar but not identical to *colourless*. Like *sox10* genetic deficiency, CAPE treatment causes a lack of semicircular canal projects and smaller, more closely spaced otoliths, but it does not decrease otic vesicle size, as has been observed in *sox10* mutants ([@bib11]). Notably, not all phenotypes of *colourless* are recapitulated by CAPE treatment, and CAPE treatment causes defects that are not explained by either Sox10 or Akt deficiency. CAPE likely has other biological targets that explain defects such as body curvature and brain ventricle enlargement. While *colourless* mutants almost entirely lack pigment cells, CAPE primarily affects melanocytes. CAPE may reduce Sox10 activity selectively depending on the target gene, with *mitfa* being one of the most strongly affected genes. One *sox10* mutant*, sox10^baz1^*, also has a strong melanocyte defect and weak xanthophore and iridophore defect ([@bib8]). This mutation causes a single amino acid substitution in the HMG DNA-binding domain of Sox10. Both CAPE and *sox10^baz1^* may selectively affect the activity of Sox10 toward specific target genes, though CAPE's effect could be indirect. CAPE has also been reported to reduce *mitfa* binding to DNA, which could be a secondary mechanism by which CAPE reduces *mitfa* target gene expression in addition to the reduced *mitfa* levels that we observed ([@bib25])

Migration defects in CAPE-treated embryos may be downstream of decreased *mitfa* expression, as in *colourless* mutants, but more direct mechanisms for inhibition of migration downstream of Akt could also play a role. Recent studies have proposed the existence of leader cells with a distinct gene expression profile that initiate neural crest migration ([@bib30]; [@bib40]). Leader cells are reported to depend on PI3K signaling for maintenance of polarity, and PI3K is known to activate Rac, a GTPase important for directed cell migration ([@bib55]). Akt can also directly phosphorylate cytoskeletal filaments and their regulators, resulting in either enhancement or repression of migration depending on context ([@bib4]). CAPE likely has an additional effect on cell migration beyond the neural crest.

We found that both CAPE treatment and constitutively active PTEN reduced the ability of Sox10 to stimulate *crestin* expression. Sox10 activity might be modified directly, through its binding partners, or through chromatin modification at its binding sites. For example, Akt inhibition could alter Sox10 dimerization or Sox10-Pax3 interaction, both of which are known to affect expression of Sox10 target genes ([@bib24]; [@bib2]; [@bib37]). Akt can directly phosphorylate transcription factors to regulate their activity, as was shown with Twist-1 in tumor cells ([@bib52]). Whether CAPE treatment and Akt inhibition affect Sox10 activity directly or indirectly will be an interesting area for future study.

Our data suggests that CAPE treatment and inhibition of Akt signaling block neural crest differentiation. Interestingly, a prior study in *Xenopus* showed an earlier and broader role for Akt in ectoderm development ([@bib36]). Pegoraro et al. found that the glycolysis regulator PFKFB4 is required for specification of all dorsal ectoderm derivatives, including neural and non-neural ectoderm, neural crest, and placodes, and acts by inhibiting Akt signaling. In contrast, our study found that inhibition of Akt signaling does not disrupt early neural crest specification but inhibits subsequent expression of Sox10 target genes, neural crest migration, and pigment cell differentiation. This apparent discrepancy could be the result of species-specific differences, or it could be related to the specificity of CAPE for inhibition of Akt stimulated by a particular ligand. We showed that in vitro CAPE inhibits FGF-stimulated Akt activation but not insulin-stimulated Akt activation. Though our study and that of Pegoraro et al. suggest different roles for Akt signaling in neural crest development, they both demonstrate that Akt signaling promotes differentiation independently of its effect on cell survival. A current challenge in neural crest biology is understanding how morphogens connect to gene expression through intracellular signaling pathways and their associated transcription factors. Our study has identified PI3K/Akt as a novel intracellular signaling pathway that regulates neural crest differentiation through modulation of Sox10 activity. Our findings may also impact the understanding and treatment of melanoma, as the Sox10 target *MITF* is a lineage oncogene in this neural crest-derived cancer ([@bib16]).

Materials and methods {#s4}
=====================

Zebrafish husbandry and strains {#s4-1}
-------------------------------

Zebrafish were maintained under standard protocols approved by the Boston Children's Hospital (BCH) Institutional Animal Care and Use Committee (IACUC). Unless indicated otherwise, AB strain embryos were used for all experiments. Additional zebrafish strains included *crestin_1 kb:EGFP* (referred to as *crestin:EGFP* here) ([@bib21]) (RRID:ZFIN\_ ZDB-TGCONSTRCT-160208--1), *crestin_296bp:EGFP* ([@bib21]) (RRID:ZFIN\_ ZDB-TGCONSTRCT-160208--2), *sox10:GFP* ([@bib7]) (RRID:ZFIN\_ ZDB-ALT-110411--1), *sox10:Kaede* ([@bib9]) (RRID:ZFIN\_ ZDB-FISH-150901--26827), *mitfa:GFP* ([@bib6]) (RRID:ZFIN\_ ZDB-FISH-150901--12193), *ubi:mCherry* ([@bib34]) (RRID:ZFIN\_ ZDB-ALT-110317--3), and *casper* ([@bib54]) (RRID:ZFIN\_ ZDB-FISH-150901--6638, *ptena-/-ptenb-/-* ([@bib14]) (RRID:ZFIN\_ ZDB-FISH-150901--12142). Zebrafish embryos were staged according to ([@bib22]).

Heterogeneous neural crest cell culture {#s4-2}
---------------------------------------

*Crestin:EGFP; ubi:mCherry* transgenic zebrafish embryos were grown to the 5 somite stage, decontaminated in 0.05% bleach for 2 min, and dechorionated in 2.5 mg/ml pronase for 5 min. Embryos were then mechanically homogenized in neural crest medium using a rotor-stator homogenizer (Omni TH) at 5000 rpm for 10 s. Neural crest medium consisted of a base medium of DMEM/F12 with L-glutamine and 2.438 g/l sodium bicarbonate (Invitrogen \#11320) supplemented with 12% FBS, 1% N2 supplement (Invitrogen \#17502), 20 μg/ml insulin (Gemini Bioproducts \#700--112P), 20 ng/ml FGF2 (R and D Systems \#233-FB-025/CF), 20 ng/ml EGF (R and D Systems \#236-EG-200), and 0.2% Primocin (InVivoGen). Embryos were plated at a density of 0.6--1 embryos per 0.1 cm^2^ (1 well of a 384 well plate) on standard tissue culture-coated plates and cultured for 24--48 hr under 5% CO~2~ at 28.5°C. N2 was excluded for short term (2 hr) cultures to test the effects of growth factor stimulation since it contains insulin.

In vitro immunofluorescence, EdU staining, and migration speed measurement {#s4-3}
--------------------------------------------------------------------------

EdU staining was conducted using the Click-iT EdU Flow Cytometry Assay Kit (Invitrogen). Zebrafish embryonic cells were plated on collagen, allowed to attach for 24 hr, and treated with 10 μM EdU for 4 hr. Cells were then fixed in 2% PFA for 30 min at RT, permeabilized in 0.5% Triton-X100/PBS, and blocked in 5% lamb serum in 0.1% Triton X-100/PBS for 1 hr at RT. Cells were incubated with primary antibody (AnaSpec anti-GFP \#55423, 1:500) in blocking buffer overnight. Cells were washed 4 times and incubated for 2 hr at RT in secondary antibody (Alexa Fluor 488 goat anti-chicken, 1:2000). Cells were washed once, and the Click-iT reaction was performed with Alexa Fluor 647 azide. Cell speed was determined using time lapse fluorescence microscopy of *crestin:EGFP*+ and *ubi:mCherry*+ cells with images acquired every 2 min. The center of each cell was manually tracked using ImageJ over a period of 4 hr, and the sum of distances migrated per frame was divided by total imaging time.

Quantitative PCR {#s4-4}
----------------

RNA was isolated using the RNeasy Plus Mini Kit (Qiagen) according to the manufacturer's instructions. RNA was quantified by absorbance at 260 nm and a standard amount was used as input to an iScript reverse transcriptase reaction (Bio-Rad). The product of this reaction was used for quantitative PCR at a maximum volume of 1 μl per 10 μl final reaction volume. Quantitative PCR was conducted using SsoFast EvaGreen Supermix (Bio-Rad) and run on a CFX384 Real-Time System/C1000 Thermal Cycler (Bio-Rad). Reactions were conducted in triplicate and normalized to β-actin. For each gene, the sample with the highest expression was assigned a value of 1 and other samples were normalized accordingly. Primer sequences are displayed in [Table 2](#table2){ref-type="table"}.
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###### Primer sequences.

  -------------------------------------------------------------------------------------------------
  Use    Gene      Forward                            Reverse                          Reference
  ------ --------- ---------------------------------- -------------------------------- ------------
  qPCR   bactin1   CGAGCAGGAGATGGGAACC                CAACGGAAACGCTCATTGC              ([@bib29])

  qPCR   sox10     ATATCCGCACCTGCACAA                 CGTTCAGCAGTCTCCACAG              

  qPCR   crestin   AGTGCCTGCCAATGTTCAC                CTGAAAAAGGCCGATGAGTT             

  qPCR   foxd3     CATGCAAAACAAGCCCAAG                ATGAGGGCGATGTACGAGTAG            

  qPCR   mitfa     GGCGGTTTAATATCAATGACAGA            GGTGCCTTTATTCCACCTCA             

  qPCR   neurog1   CGTGCCATTATCTTCAACACA              CGATCTCCATTGTTGATAACCTT          

  qPCR   myf5      GCTACAACTTTGACGCACAAAA             CACGATGCTGGACAAACACT             

  qPCR   runx1     CGTCTTCACAAACCCTCCTCAA             GCTTTACTGCTTCATCCGGCT            

  ISH    tfap2a    TAATACGACTCACTATAGGGAATCT\         AATTAACCCTCACTAAAGGTCAC\         
                   TCACAGATGTTAGTGCACAGTTTTTCCGCGAT   TTTCTGTGCTTCTCATCTT              

  ISH    tfap2c    TAATACGACTCACTATAGGGACAG\          AATTAACCCTCACTAAAGGTCA\          
                   AAACAACATGTTGTGGAAATTAGCAGATAA     CTTTCGGTGTTTGTCCATCTT            

  ISH    inka1a    AATTAACCCTCACTAAAGGG\              TAATACGACTCACTATAGGGATGG\        
                   GAATCGGGTGACTGTCTGC                GTGTTCTGCTCCCAG                  

  ISH    dlx2a     AATTAACCCTCACTAAAGGACAA\           TAATACGACTCACTATAGGGACAGGC\      
                   CAGCATGAACAGCGTC                   GCATGAAACACAT                    

  ISH    pax7a     AATTAACCCTCACTAAAGGAGAA\           TAATACGACTCACTATAGGTTGATC\       
                   CTACCCACGAACCGGA                   TGTGAAGCGTGCTG                   

  ISH    myca      TAATACGACTCACTATAGGGCAAG\          AATTAACCCTCACTAAAGGTTAATGTG\     
                   TGTCAAAATGCCGGTGAGTGCGAGTTTGGCGT   AACTCCGCAGCTGCTGAA               

  ISH    ets1      TAATACGACTCACTATAGGGTGTA\          AATTAACCCTCACTAAAGGTCAGGAGC\     
                   CGTTTGAATGCGTGACCATGACGGCAGCTGT    TCCAACAGGAACTGCCAGA              

  ISH    nr2f2     TAATACGACTCACTATAGGGTAGATATGGC\    AATTAACCCTCACTAAAGGCTACTGAAT\    
                   AATGGTAGTGTGGAGAGGCTCCCA           CGACATATAAGGCCAGTT               

  ISH    msx1b     TAATACGACTCACTATAGGGGATGGTTAA\     AATTAACCCTCACTAAAGGTTAAGAC\      
                   CGATGAATTCTCCTAAGGGACCCGTT         AAATAATACATCCCATA                

  ISH    dlx5a     TAATACGACTCACTATAGGGTTATCCAA\      AATTAACCCTCACTAAAGGTCAGTACAAC\   
                   ACTATGACTGGAGTATTCGACAGAAGGA       GTTCCTGATCCGAGTGCCAA             
  -------------------------------------------------------------------------------------------------

Intradermal cell transplantation {#s4-5}
--------------------------------

Heterogeneous neural crest cell cultures were sorted for DAPI negative, crestin:EGFP+ cells and resuspended in PBS at a concentration of 10,000 cells/μl. Cell suspension was loaded into a glass syringe with a 33 gauge needle (Hamilton), and 0.5 μl was injected underneath a scale on the dorsal flank of a *casper* fish irradiated with 15 Gy per day for two consecutive days. Transplants were conducted on the third day.

Chemical screening and hit determination {#s4-6}
----------------------------------------

Embryos were plated with chemicals at 5 ss in 384-well plates as described in heterogeneous NC cultures. Cells were cultured for 1 day, Hoechst 33342 was added at a final concentration of 0.3 μg/ml, and wells were imaged in red, green, and blue channels on a Nikon Eclipse Ti Spinning Disk Confocal. Chemicals libraries included LOPAC1280, a custom bioactives library, FDA-approved drugs, and Chembridge KINAcore and NHRcore libraries. Chemicals were screened in triplicate at two concentrations depending on the library. Hits were identified based on deviation from plate controls in two values: ratio of *crestin:EGFP*+/*ubi:mCherry*+ cells and *crestin:EGFP*+/total nuclei. All hits were verified by eye.

Chemical treatment of zebrafish embryos {#s4-7}
---------------------------------------

Unless otherwise indicated, embryos were treated at 2 ss. To reach this time point, embryos fertilized in the morning were either incubated at 28.5°C for 12 hr or 23°C for the first 6 hr of development, then transferred to 19°C overnight. Embryos fertilized in the afternoon were incubated at 23°C overnight. Chemical stocks were maintained in DMSO, resulting in a final concentration of no more than 0.3% DMSO in E3 embryo medium. Embryos at a maximum density of 20/well were treated in 24 well plates in 1 ml of chemical solution at 28.5°C protected from light. CAPE was obtained from Tocris (cat \#2743) and used at a concentration of 10 μM unless otherwise indicated.

Fluorescence activated cell sorting {#s4-8}
-----------------------------------

Cell sorting was conducted on a BD FACSAria IIu using a nozzle diameter of 80 μm. For whole embryo FACS, embryos were mechanically homogenized in FACS buffer (2% FBS in PBS), passed through a 40 μm cell strainer and kept on ice until sorting. DAPI was added at a final concentration of 1 μg/ml to distinguish live from dead cells. Cells were collected in media or FACS buffer and kept on ice until further analysis. For *crestin:EGFP* sorting, the ratio of GFP to PE signal was used to distinguish autofluorescence from GFP fluorescence.

Imaging of zebrafish embryos {#s4-9}
----------------------------

Epifluorescence and bright field images were obtained using a Zeiss Discovery V.8 Stereoscope with an Axiocam HRc. Confocal microscopy of flat-mounted embryos was conducted on a Nikon C2si Laser Scanning Confocal. Time lapse confocal microscopy of live embryos was conducted on a Nikon Eclipse Ti Spinning Disk Confocal. Embryos were mounted on 6 well imaging plates in 0.8% low melting point agarose containing 0.003% 1-phenyl-2-thiourea (PTU) to prevent pigmentation, 1.6 μg/ml tricaine (MS-222) to immobilize fish, and the relevant concentration of CAPE. Embryos were maintained at 28.5°C during imaging.

Whole mount in situ hybridization, immunofluorescence, and TUNEL {#s4-10}
----------------------------------------------------------------

Whole mount in situ hybridization was conducted as described ([@bib47]; [@bib49]; [@bib27]). The following probes were generated from established plasmids: *crestin *([@bib41]), *pax3 *([@bib44]), *foxd3*, *sox10*, and *snai1b *([@bib48]). Plasmid templates were linearized using an appropriate restriction enzyme and PCR purified prior to in vitro transcription. Other in situ probes were generated from PCR products containing a T7 promoter: *tfap2a*, *tfap2c*, *inka1a*, *dlx2a*, *pax7a*, *myca*, *ets1*, *nr2f2*, *msx1b*, *dlx5a*. See [Table 2](#table2){ref-type="table"} for primer sequences. RNA was isolated from 17 ss embryos using the RNeasy Plus Mini Kit (Qiagen). A cDNA library was synthesized using the SuperScript III First Strand Synthesis System (Invitrogen). PCR was conducted using Phusion High-Fidelity DNA Polymerase (NEB), and products were purified prior to in vitro transcription with the following components: Roche Dig 11277073910, BCIP/NBT S3771, Roche T3 or T7 polymerase, RNaseIn (Promega).

For whole mount immunofluorescence, zebrafish embryos were fixed in 4% PFA overnight at 4°C. Embryos were permeabilized in acetone at −20°C for 7 min, blocked for 30 min in blocking buffer (2% BSA, 10% lamb serum, 1% DMSO in PBS-0.1% Triton X-100) and incubated in primary antibodies in blocking buffer overnight. Embryos were washed twice for 30 min in PBS-0.1% Triton X-100, then incubated for 2 hr with secondary antibodies at room temperature. Anti-phospho-H3 antibody was obtained from Santa Cruz Biotechnology (rabbit polyclonal, sc-8656-R, 1:750) and anti-GFP was from Genetex (chicken polyclonal, GTX13970, 1:500). Secondary antibodies were from Thermo Fisher (goat anti-rabbit IgG Alexa Fluor 555, goat anti-chicken Alexa Fluor 488, both 1:1000).

Whole mount TUNEL was conducted after *crestin* in situ hybridization using the ApopTag Peroxidase In Situ Apoptosis Detection Kit (EMD Millipore) with extended incubation times. Signal was visualized with SIGMAFAST 3,3-Diaminobenzidine tablets (Sigma).

RNA-seq {#s4-11}
-------

Total RNA was extracted from sorted s*ox10:GFP*+ cells using Trizol LS according to the manufacturer\'s instructions. Libraries were prepared using the Ribogone kit (Clontech) and the SMARTer Universal Low RNA Kit (Clontech) according to the manufacturer's instructions. Libraries were analyzed on a Fragment Analyzer (Advanced Analytical) and quantified using the Qubit (Invitrogen) prior to sequencing on the Illumina HiSeq 2500. Quality control of RNA-Seq datasets was performed by FastQC and Cutadapt to remove adaptor sequences and low quality regions. The high-quality reads were aligned to UCSC build danRer7 of the zebrafish genome using Tophat 2.0.11 without novel splicing form calls. Transcript abundance and differential expression were calculated with Cufflinks 2.2.1. FPKM values were used to normalize and quantify each transcript.

Plasmids {#s4-12}
--------

Myr-Akt1 was a gift from William Sellers (Addgene plasmid \#9008) ([@bib39]). pCSDest was a gift from Nathan Lawson (Addgene plasmid \# 22423). PTEN QMA-mCherry was from [@bib46].

Western blotting {#s4-13}
----------------

Cultured cells were collected on ice, pelleted at 500 rcf for 3 min at 4°C, washed once with ice-cold PBS, and lysed in RIPA buffer containing protease and phosphatase inhibitors. Embryos were dechorionated, deyolked on ice in 55 mM NaCl, 1.8 mM KCl, 1.3 mM NaHCO~3~, centrifuged at 500 rcf for 3 min at 4°C, and washed once in 110 mM NaCl, 3.5 mM KCl, 2.7 mM CaCl~2~, 10 mM Tris pH 8.5 prior to lysis as for cultured cells. Lysate was centrifuged at 20,000 rcf for 10 min and the supernatant was collected for analysis of protein concentration with the DC Protein Assay (Bio-Rad). Samples were boiled in Laemelli buffer before loading of 10 μg protein per well of a 4--20% polyacrylamide gel. Protein was transferred to a PVDF membrane using the iBlot dry blotting system (Invitrogen), blocked in 5% milk in TBS with 0.1% Tween 20, and incubated in primary antibody in 5% BSA overnight at 4°C. Blots were washed, incubated in horse radish peroxidase (HRP)-conjugated secondary antibody for 1 hr at room temperature, washed again, and developed using Amersham ECL Prime Western Blotting Detection Reagent (GE Healthcare) or Pierce ECL Western Blotting Reagent (Thermo Fisher Scientific). Antibodies were obtained from Cell Signaling: Erk (\#9102, RRID:[AB_330744](https://scicrunch.org/resolver/AB_330744), 1:1000), Akt (\#9272, RRID:[AB_329827](https://scicrunch.org/resolver/AB_329827), 1:1000), phospho-Akt (\#9271, RRID:[AB_329825](https://scicrunch.org/resolver/AB_329825), 1:1000), phospho-Erk (\#9101, RRID:[AB_331646](https://scicrunch.org/resolver/AB_331646), 1:1000), GAPDH (\#2118, RRID:[AB_561053](https://scicrunch.org/resolver/AB_561053), 1:2000), HRP-linked anti-rabbit IgG (\#7074, RRID:[AB_2099233](https://scicrunch.org/resolver/AB_2099233), 1:2000).

RNA microinjection {#s4-14}
------------------

Constructs were cloned into pCSDest ([@bib53]), linearized, transcribed using the Ambion mMessage mMachine SP6 Kit (Thermo Fisher Scientific), and purified with the RNeasy MinElute RNA Cleanup Kit (Qiagen). RNA was quantified based on absorbance at 260 nm and injected with 0.1% phenol red into 1--2 cell embryos in a volume of 1--2 nl.

ATAC-seq {#s4-15}
--------

Cells (12,000--40,000) were pelleted at 500 rcf for 5 min at 4°C, washed once in ice cold PBS, and permeabilized in 10 mM Tris-HCl pH 7.4, 10 mM NaCl, 3 mM MgCl2, 0.1% IGEPAL CA-360. Libraries were prepared using the Nextera DNA Preparation Kit (Illumina) with a transposase reaction time of 30--45 min and purified with the MinElute PCR Purification Kit (Qiagen). Quantitative PCR was used to estimate the total number of cycles needed for library amplification. Libraries were analyzed on a Fragment Analyzer (Advanced Analytical) and quantified using the Qubit (Invitrogen) prior to sequencing on the Illumina HiSeq 2500. ATAC-Seq datasets were aligned to UCSC build danRer7 of the zebrafish genome using Bowtie2 (version 2.2.1) with the following parameters: \--end-to-end, -N0, -L20. We used the MACS2 version 2.1.0 peak finding algorithm to identify regions of ATAC-Seq peaks, with the following parameter \--nomodel \--shift −100 \--extsize 200. A q-value threshold of enrichment of 0.05 was used for all datasets. HOMER was used for peak motif analysis (RRID:[SCR_010881](https://scicrunch.org/resolver/SCR_010881)).
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Major datasets {#s7}
--------------

The following dataset was generated:

Ciarlo CKaufman CKKinikoglu BMichael JYang SD\'Amato CBlokzijl-Franke Sden Hertog JSchlaeger TMZhou YLiao ECZon LI2017A chemical screen in zebrafish embryonic cells establishes that Akt activation is required for neural crest development<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE95815>Publicly available at the NCBI Gene Expression Omnibus (accession no: GSE95815)

The following previously published dataset was used:

Kaufman CKMosimann CFan ZPYang SThomas AJAblain JTan JLFogley RDvan Rooijen EHagedorn EJCiarlo CWhite RMMatos DAPuller ACSantoriello CLiao ECYoung RAZon LI.2016A zebrafish melanoma model reveals emergence of neural crest identity during melanoma initiation<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE75356>Publicly available at the NCBI Gene Expression Omnibus (accession no: GSE75356)

10.7554/eLife.29145.063

Decision letter

Whitfield

Tanya T

Reviewing Editor

University of Sheffield

United Kingdom

In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

\[Editors' note: a previous version of this study was rejected after peer review, but the authors submitted for reconsideration. The first decision letter after peer review is shown below.\]

Thank you for submitting your work entitled \"A chemical screen in zebrafish embryonic cells establishes that Akt activation is required for neural crest development\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, one of whom is a member of our Board of Reviewing Editors, and the evaluation has been overseen by a Senior Editor. The reviewers have opted to remain anonymous.

Our decision has been reached after consultation between the reviewers. Based on these discussions and the individual reviews below, we regret to inform you that your work will not be considered further for publication in *eLife* at the present time. The reviewers all found the study interesting and potentially important, and highlighted the design of the screening assay as a strength of the study. However, there were concerns over the specificity of some of the experimental approaches, quantitation of the data, and degree of advance and mechanistic insight over previously published work. The reviewers have identified a list of revisions, but it was felt that it would be unrealistic to expect that these could be completed within a timeframe of two months.

As it is the policy of *eLife* to only encourage resubmission of papers that can modified within a relatively short timeframe, I have no choice but to decline the present version of the paper. If in the future you feel you can address the detailed comments of the reviewers, we would be open to receiving a new version of the manuscript and make every effort to the paper to the original reviewers.

Reviewer \#1:

This is an interesting study that has identified compounds that interfere with neural crest development using an in vitro-based screening assay followed by validation in vivo in the zebrafish embryo. The study focusses on one compound, CAPE, which shows a dose-dependent reduction in sox10 activity. The authors provide evidence to show that CAPE mediates its effects through inhibition of PI3K/Akt signalling in FGF-stimulated cells, resulting in abnormal neural crest development and some other embryonic defects. The study uses a range of experimental approaches to support the main conclusions. I have a few suggestions for improved clarity or presentation of the data.

1\) Although the main conclusion is that CAPE acts by reducing Sox10 activity, it should be pointed out more explicitly that the phenotype of CAPE-treated embryos does not resemble that of sox10 mutants closely. The neural crest defects (pigmentation) are less severe, while other aspects (e.g. body curvature and length, pericardial oedema, small head and eyes etc) are more severe. The current text only highlights similarities. The authors point out that CAPE only appears to affect sox10 activity at some promoters, but I think it would be helpful to have show a more detailed comparison with the known effects of the genetic loss of sox10 function. For example, sox10 mutants lack all three pigment cell types, not just melanophores. Are all three pigment cell types reduced in the CAPE-treated embryos, or does treatment only affect the melanophores? (Clearly, some xanthophores are still present, given the yellow colouration of the head in CAPE-treated embryos.) Iridophores should also be checked, since these are missing in sox10 mutants, but are increased at the expense of melanophores in mitfa mutants (Lister et al., 1999).

2\) The other major site of sox10 expression in the embryo is the ear, and sox10 mutant embryos are known to have a very strong ear phenotype (Dutton et al., 2009). Does CAPE treatment also recapitulate these otic defects? If yes, this would support the interpretation that CAPE acts via Sox10, and if no, it might reveal interesting differences in target gene activity for Sox10 between the ear and the neural crest.

3\) With respect to the effects on the embryo such as body curvature, which are unlikely to be attributed to a loss of Sox10 activity, what is the interpretation? Are there any more general effects on cell behaviour? The video showing reduced cell migration is clear, but is there a general inhibition of cell migration? What happens to other migratory cell types e.g. the lateral line primordium?

4\) The HOMER analysis ([Figure 3C](#fig3){ref-type="fig"}) is supposed to identify transcription factors in an unbiased manner, and clearly has generated a lot of data. Only the data for the Sox10 and Mitf motifs are shown, though. It is stated that these are the most enriched, but it would be helpful to show how these compare to say, the next three most enriched in the dataset -- otherwise this just looks like confirmation of a result that was already predicted.

5\) It is not clear where the two PI3K inhibitors (described as \'strong hits\') appear in [Table 1](#table1){ref-type="table"} -- please highlight these. PI3K inhibition is not mentioned for any of the compounds in the Target column. More generally, it would help if this Table conveyed more information. For example, do the hits fall into clear groups based on structural similarities?

Reviewer \#2:

This is a very interesting manuscript in which the authors have identified a specific role for pAKT in the progressive acquisition of NC status. The authors here report another success from an ingenious screen, using a mixture of embryonic cells from early stages of development in which NC have been specified, and remain sensitive to modulation. They identify CAPE as a molecule able to inhibit pAKT when NC development is under way (specified). This inhibition of AKT leads to clear defects in the progression of NC development through alteration of expression of NC genes, reporters, melanocyte formation, and migration. Furthermore, AKT inhibition seems to specifically alter SOX10 activity, which in turn mediates at least some of the other NC effects noted.

Their exploration of putative pathway contributions reveals that while CAPE effects on AKT and NC development rely on FGF2 (and perhaps pERK), alternative inhibition of pAKT through other molecules, does lead to AKT inhibition and NC deficits independently of FGF2. This is a solid work with novel insights of signaling that should be very welcomed by the developmental biologists and the neural crest community alike. However a few important concerns are pointed below:

The description made for the IH results lacks a) temporal context of expression of specific genes, and b) a proper quantification. The result comments are qualitative and subjective, (for example the authors suggest a robust change on SOX10 via IH, which is and also lack spatiotemporal context. Are early genes spared alterations triggered by CAPE? Does CASPE only alters later NC markers?, all later NC markers? The RNAseq data from sox10:Kaede+ provides quantifiable data, this suggest minimal effect on Sox10, yet significant changes in other genes (Pax3). A better analysis of the regional pattern for IH along with possible limitations of the transgenic line (does it collect all NC?, could subpopulations be missed by this line?) seems warranted, and will be particularly interesting given the ATAC analysis was also performed on this population.

While describing changes in expression based on IH, the authors bundle SOX10 Crestin and Pax7 as being all dramatically reduced and place other genes like FoxD3, Snai1b, or Inka1a as regionally affected. It is not clear from the images provided that SOX10, or even crestin, are not differentially affected by region. Pax7 instead does seem to be eliminated in normal NC associated regions. In the other hand genes like Pax7, Pax3 and Ets1 seem to increase in Non-NC territories. Additionally, the authors state that genes like Pax3 and Ets1 do not change their profiles in NC territory, yet some of the images provided do not allow a clear conclusion.

It is worth noting that the authors suggest that CAPE and AKT play a role in late events, yet no tests for earlier effects were performed.

While addressing cell death and proliferations the authors quantified effects over region when they have the opportunity to specifically address changes over GFP+ neural crest. While the authors suggest that the dramatic effects in cell death arise late, it seems relevant that the cell death increased at 10µM CAPE, the same concentration used through several other experiments.

The pathway analysis results regarding signaling ligands are not very informative in their current format due to over and under expression of the same pathways. And would suggest to remove this portion.

The Materials and methods section reports that embryonic cell cultures medium contains 12% FBS and N2 (Insulin 5µg/ml), however they do not provide any arguments or considerations regarding these components while addressing the effect of specific signals at multiple points. Did they remove the N2 while addressing FGF2 or Insulin? Certainly FBS has potential interfering components that should have been noted.

It might be relevant to test if other AKT inhibitors (Pi-103 [Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}) could inhibit pAKT triggered by Insulin, FGF2 and iMEK.

The ERK-PI3K analyses were done in zebrafish cell cultures and report broad activity and effects of molecules on signaling. They may not represent signaling effects mediated by NC.

Regarding the model provided in [Figure 6](#fig6){ref-type="fig"} panel E, while ERK activation might block PIP3, this is context dependent. In the experiments here addressed, it seems that ERK inhibition does boost pPI3K, however under Insulin FGF2 activity, robust pERK does not seem to reduce pAKT, and thus the solid line of inhibition between Erk and PI3P might be misleading.

Reviewer \#3:

The authors have carried out a chemical screen to identify compounds that reduce expression crestin:gfp in a mixed culture of primary cell derived from dissociated transgenic zebrafish embryos. They focus on one compound, CAPE, and find that it reduces expression of neural crest markers in zebrafish, a few hours before leading to widespread cell death. They provide evidence that CAPE acts upstream of phospho-Akt, a well-known regulator of cell viability.

Mechanistic insight from the manuscript is very limited. I would like to see more depth at one level or another. For instance, it is unclear where CAPE acts. The authors mention a paper in which CAPE was shown to inhibit PI3K activity. Is this the authors\' preferred model for the principal locus of control of CAPE in the control of gene expression in NC? If so, why does it depend on FGF signaling? The proposed requirement for FGF signaling is not entirely convincing with the data shown. [Figure 6](#fig6){ref-type="fig"} is rather baffling. CAPE is said to be ineffective in the absence of FGF. But even in the absence of added FGF there must be some basal level of RAS/RAF/ERK/MEK signaling, because addition of a MEK inhibitor massively up regulates the amount of phospho-AKT. The bar chart suggests there is some effect of CAPE, but it does not reach significance. Does constitutively active PI3K rescue the effects of CAPE? This seems unlikely because CA-Akt only partially does so, and loss of pten LOF does not seem to do so. \[As an aside, the pten mutant data is buried and is under-explained ([Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}). Comparing [Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}, to [Figure 3E](#fig3){ref-type="fig"} makes is appear that ptena -/-; ptenb +/- have an elevated level of crestin in comparison to wild-types. Is that true? Do the double mutants have other phenotypes accompanying the elevated crestin?\] Returning to the question of the locus of CAPE activity, does CAPE work to reduce p-AKt levels in ptena/b double mutants? Do the PI3K inhibitors work to rescue elevate crestin in such double mutants? If not, then perhaps PI3K really is the central locus of control. There is more to learn from this mutant that would help point to the locus of CAPE action.

Another option for mechanistic insight that would elevate the significance of the study would be to dig deeper into the transcriptional regulation. What causes the chromatin to close at the MITF promoter? As the authors noted, Β-catenin is regulated by AKT, and loss of β-catenin activity potentially explains many of the phenotypes described here. The authors show that forced expression of sox10 no longer elevates crestin expression in CAPE-treated embryos and claim that CAPE controls Sox10 activity. However, they provide no evidence for specificity. Would forced expression of another master regulator be similarly disempowered by CAPE expression? The ATAC-seq data is an interesting start, but the authors do not go anywhere with it. By what mechanism does the MITF promoter, but not the PDGFR promoter, become closed upon CAPE treatment? The fact that Sox10 binds both promoters indicates that Sox10 is not likely to be part of the differential effect. What happens to the promoter of Tyrosinase? The authors should probably cite an earlier study showing that 1 μm CAPE, which had no effect on p-AKT, altered the binding of MITF to the Tyrosinase promoter (J Nat Prod. 2013 Aug 23;76([@bib8]):1399-405.)

It appears that some markers, e.g., crestin, are globally in NCN while others, e.g. dlx2a and snai1b, are lost just regionally. Is the region where gene expression is lost the same for all markers with regional loss? What is the relationship of time-of-initiation-of-gene-expression and sensitivity to inhibition by CAPE? Is it as simple as CAPE extinguishes all new gene expression? For instance, if CAPE is applied at shield stage, is induction of the neural plate border markers suppressed? If this is the case, then it is misleading to present CAPE as an inhibitor of neural crest induction.

Related to the previous point, a highly relevant study (Pegoraro et al., 2015), oddly not mentioned by the authors but easily discovered through a Pubmed search on \"neural crest AKT\", it was shown that knockdown of PFKFB4 results in loss of all new gene expression within dorsal embryo, i.e., the domain in which PFKFB4 is expressed, concomitant with loss of p-Akt; all such expression was restored by over-expression of constitutively active Akt. This suggests that the CAPE by reducing p-Akt is a general suppressor of new gene expression, possibly as a consequence of activation (but not completion) of a cell death pathway. The current study offers less mechanistic insight than this previously published work.

It seems plausible that CAPE is simply toxic, by virtue of inhibiting of PI3K and Akt pathways, resulting in reduced gene expression on the way to cell death. In the Pegoraro paper they argue against the possibility by showing that apoptosis could be uncoupled from the defects in gene expression (i.e., by over expression of BCl^-^Xl), but even such an experiment does not rule out the possibility that loss of gene expression results from initiation, but not completion, of an apoptosis program.

\[Editors' note: what now follows is the decision letter after the authors submitted for further consideration.\]

Thank you for resubmitting your work entitled \"A chemical screen in zebrafish embryonic cells establishes that Akt activation is required for neural crest development\" for further consideration at *eLife*. Your revised article has been favorably evaluated by Marianne Bronner (Senior editor), a Reviewing editor, and two reviewers.

All three reviewers are positive about the study and are happy that you have addressed their concerns. Detailed comments from reviewers 1 and 2 are shown below for your information, but after discussion, it was agreed that further experiments are not necessary before publication.

Reviewer \#1:

In the revised manuscript Ciarlo and co-authors have addressed, to some degree, my two chief reservations about the first submission. The first was I felt the study did not make a conceptual advance beyond those in the Pegoraro et al.,2015 paper. These authors showed that inhibition of PFKFB4 reduced p-Akt levels and prevented expression of markers of NC and other ectoderm derivatives, and that forced expression of constitutively-active Akt rescued expression of these markers in PFKFB4-morphants. In the revised manuscript Ciarlo et al. now acknowledge the Pegoraro et al. study and point out, legitimately, where their findings differ from it.

The second reservation I had was about the limited mechanistic insight. The revised paper is somewhat improved in this regard because it now presents a clearer model for where CAPE functions. It remains quite mysterious how CAPE affects Sox10 activity at some targets and not at others, but this point is acknowledged in the Discussion it is reasonable to leave this issue for the next paper. The PTEN-overexpression experiment nicely illuminate the aspects of the CAPE-mediated phenotype that are likely to result from inhibition of Akt, which is most but not all of them.

There are additional strengths of the project that will be useful for the field, for instance showing that cultured, GFP-positive NC express appear to express sox10 and foxd3 at about the same level as freshly harvested ones. Another strength is the experimental pipeline of screening compounds that have a greater effect on a tissue specific reporter than ubiquitously expressed one.

Reviewer \#2:

The authors have modified the original manuscript adding a few experiments and multiple requested items (better imaging and quantifications) and have improved the manuscript considerably. However, PI3K-AKT was known to modify dorsal ectoderm fates, including NC. The results of this manuscript suggest that AKT effect is restricted to later NC events and does not alter other dorsal ectoderm fates. They propose that animal model differences account for the discrepancy between this zebrafish study and the previous *Xenopus* study. Their data is consistent with this view.

The authors suggest that CAPE acts upstream of PI3K, and confirmed both crestin and pigment cell phenotypes in vivo with various inhibitors. Their postulate that AKT operates differently in these organisms rests on the expression of genes associated with pre- and migratory NC. Yet, they do not provide the effect on these genes with other PI3K and AKT inhibitors. The suggested experiments could confirm their model (probing that AKT does not alter broadly dorsal ectoderm fates. Alternatively, a common effect of AKT in both organisms could emerge, and suggest a distinct AKT-modulation by CAPE.

10.7554/eLife.29145.064

Author response

\[Editors' note: the author responses to the first round of peer review follow.\]

> Reviewer \#1:
>
> This is an interesting study that has identified compounds that interfere with neural crest development using an in vitro-based screening assay followed by validation in vivo in the zebrafish embryo. The study focusses on one compound, CAPE, which shows a dose-dependent reduction in sox10 activity. The authors provide evidence to show that CAPE mediates its effects through inhibition of PI3K/Akt signalling in FGF-stimulated cells, resulting in abnormal neural crest development and some other embryonic defects. The study uses a range of experimental approaches to support the main conclusions. I have a few suggestions for improved clarity or presentation of the data.
>
> 1\) Although the main conclusion is that CAPE acts by reducing Sox10 activity, it should be pointed out more explicitly that the phenotype of CAPE-treated embryos does not resemble that of sox10 mutants closely. The neural crest defects (pigmentation) are less severe, while other aspects (e.g. body curvature and length, pericardial oedema, small head and eyes etc) are more severe. The current text only highlights similarities. The authors point out that CAPE only appears to affect sox10 activity at some promoters, but I think it would be helpful to have show a more detailed comparison with the known effects of the genetic loss of sox10 function. For example, sox10 mutants lack all three pigment cell types, not just melanophores. Are all three pigment cell types reduced in the CAPE-treated embryos, or does treatment only affect the melanophores? (Clearly, some xanthophores are still present, given the yellow colouration of the head in CAPE-treated embryos.) Iridophores should also be checked, since these are missing in sox10 mutants, but are increased at the expense of melanophores in mitfa mutants (Lister et al., 1999).

We agree with the reviewer that a more extensive comparison of CAPE and sox10 mutants is informative. Though CAPE-treated embryos share similarities with sox10 mutants, there are also differences that we have now presented more explicitly in the manuscript. Although many of the early sox10 phenotypes are recapitulated by CAPE, there are more severe neural crest defects in the sox10 mutants, and CAPE has some effects distinct from the sox10 mutants. In sox10 null mutants, all pigment cells are severely reduced. We have now included an analysis of xanthophores and iridophores in CAPE-treated embryos. We found that the xanothophore marker fms was dramatically decreased in CAPE-treated embryos at 24 hpf, but xanothophores recovered by 3 dpf, as indicated by the intense yellow coloring in the head of CAPE-treated embryos ([Figure 1D](#fig1){ref-type="fig"}, [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). Iridophores were decreased at 3 dpf in CAPE-treated embryos, but not as dramatically as melanophores ([Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). Iridophores also displayed a less dramatic migration phenotype than melanophores based on the fraction of dorsal iridophores. One sox10 mutant, sox10baz1, shows a similar effect in which melanophores are more dramatically reduced than other pigment cells (Delfino-Machin et al., 2017). CAPE likely does not fully inhibit sox10 activity at least at concentrations with no overt toxicity. CAPE leads to some other effects on the body that are not found in sox10 mutants, but overall the early effects of CAPE are rather similar to sox10 mutants. We have adjusted the text to be more explicit about these differences (see Discussion).

> 2\) The other major site of sox10 expression in the embryo is the ear, and sox10 mutant embryos are known to have a very strong ear phenotype (Dutton et al., 2009). Does CAPE treatment also recapitulate these otic defects? If yes, this would support the interpretation that CAPE acts via Sox10, and if no, it might reveal interesting differences in target gene activity for Sox10 between the ear and the neural crest.

We found that CAPE caused an otic vesicle phenotype that was similar to that observed in sox10 mutants. Both caused a subtle change in otic vesicle shape at 24 hpf and a severe defect by 48 hpf including lack of semicircular canal projections and smaller, more closely spaced otoliths. However, we did not observe a change in size of the otic vesicle as in sox10 mutants.

> 3\) With respect to the effects on the embryo such as body curvature, which are unlikely to be attributed to a loss of Sox10 activity, what is the interpretation? Are there any more general effects on cell behaviour? The video showing reduced cell migration is clear, but is there a general inhibition of cell migration? What happens to other migratory cell types e.g. the lateral line primordium?

CAPE indeed has effects on embryonic development that are not related to the neural crest. While it is unclear what target of CAPE is responsible for the body curvature phenotype, it is likely not related to sox10 or Akt activity since embryos deficient in these genes do not display such a phenotype. We found that 5 μM CAPE also slightly inhibited migration of the lateral line primordium based on position of neuromasts at 2 dpf:

This phenotype be related to CAPE's activity as an Akt inhibitor since Akt is known to play an important role in cellular migration. CAPE likely has an additional non-cell type specific effect on cell migration beyond its effect on sox10 activity/mitfa expression. We have modified the Discussion to include this point.

> 4\) The HOMER analysis ([Figure 3C](#fig3){ref-type="fig"}) is supposed to identify transcription factors in an unbiased manner, and clearly has generated a lot of data. Only the data for the Sox10 and Mitf motifs are shown, though. It is stated that these are the most enriched, but it would be helpful to show how these compare to say, the next three most enriched in the dataset -- otherwise this just looks like confirmation of a result that was already predicted.

We agree with the reviewer that there might have been other sites than sox10 and MITF that would be enriched, but the only sites that were differentially affected were similar to Sox and MITF motifs. We have added the top 10 enriched motifs to the figure, but all of these motifs are similar to Sox or MITF binding sites.

> 5\) It is not clear where the two PI3K inhibitors (described as \'strong hits\') appear in [Table 1](#table1){ref-type="table"} -- please highlight these. PI3K inhibition is not mentioned for any of the compounds in the Target column. More generally, it would help if this Table conveyed more information. For example, do the hits fall into clear groups based on structural similarities?

[Table 1](#table1){ref-type="table"} initially indicated only hits that were validated in vivo. We have modified the table to include all hits that validated in vitro and highlighted the hits that validated in vivo.

> Reviewer \#2:
>
> This is a very interesting manuscript in which the authors have identified a specific role for pAKT in the progressive acquisition of NC status. The authors here report another success from an ingenious screen, using a mixture of embryonic cells from early stages of development in which NC have been specified, and remain sensitive to modulation. They identify CAPE as a molecule able to inhibit pAKT when NC development is under way (specified). This inhibition of AKT leads to clear defects in the progression of NC development through alteration of expression of NC genes, reporters, melanocyte formation, and migration. Furthermore, AKT inhibition seems to specifically alter SOX10 activity, which in turn mediates at least some of the other NC effects noted.
>
> Their exploration of putative pathway contributions reveals that while CAPE effects on AKT and NC development rely on FGF2 (and perhaps pERK), alternative inhibition of pAKT through other molecules, does lead to AKT inhibition and NC deficits independently of FGF2. This is a solid work with novel insights of signaling that should be very welcomed by the developmental biologists and the neural crest community alike. However a few important concerns are pointed below:
>
> The description made for the IH results lacks a) temporal context of expression of specific genes, and b) a proper quantification. The result comments are qualitative and subjective, (for example the authors suggest a robust change on SOX10 via IH, which is and also lack spatiotemporal context. Are early genes spared alterations triggered by CAPE? Does CASPE only alters later NC markers?, all later NC markers? The RNAseq data from sox10:Kaede+ provides quantifiable data, this suggest minimal effect on Sox10, yet significant changes in other genes (Pax3). A better analysis of the regional pattern for IH along with possible limitations of the transgenic line (does it collect all NC?, could subpopulations be missed by this line?) seems warranted, and will be particularly interesting given the ATAC analysis was also performed on this population.

We acknowledge that the gene expression data was presented in a confusing manner and have modified the figure and text to improve it. We have now included the temporal context of gene expression. The genes which had decreased expression were confined to markers of the premigratory and migratory neural crest. Those that are expressed earlier at the neural plate border stage were unchanged. However not all premigratory/migratory neural crest markers were changed, consistent with a block in differentiation of neural crest cells. For example, mitfa and inka1a were decreased, and like crestin these are downstream targets of neural crest specifiers, sox10 and ap2 respectively. The reviewer brings up a good point that using sox10:Kaede+ cells to analyze neural crest gene expression produces inherent biases. The sox10:Kaede transgenic line is more highly expressed in the cranial neural crest, which could contribute to discrepancies in the in situ data compared to the RNA-seq data. Sox10: Kaede is also highly expressed in the otic vesicle, so it is not strictly confined to neural crest. We have now included a statement of these biases in the text.

> While describing changes in expression based on IH, the authors bundle SOX10 Crestin and Pax7 as being all dramatically reduced and place other genes like FoxD3, Snai1b, or Inka1a as regionally affected. It is not clear from the images provided that SOX10, or even crestin, are not differentially affected by region. Pax7 instead does seem to be eliminated in normal NC associated regions. In the other hand genes like Pax7, Pax3 and Ets1 seem to increase in Non-NC territories. Additionally, the authors state that genes like Pax3 and Ets1 do not change their profiles in NC territory, yet some of the images provided do not allow a clear conclusion.

We have now included a scoring of the ISH experiments to address the issue of quantification. We found that several of the genes with regional expression changes did not show significant changes and moved them to [Figure 2---figure supplement 2](#fig2s2){ref-type="fig"} as genes with little to no change upon CAPE treatment. We have also enlarged the panels in [Figure 2](#fig2){ref-type="fig"} to make it easier to see the changes in gene expression upon CAPE treatment. While CAPE did increase the yolk background staining for some probes, this was likely not real expression and did not correlate with whether the gene changed in expression upon CAPE treatment.

> It is worth noting that the authors suggest that CAPE and AKT play a role in late events, yet no tests for earlier effects were performed.

We did evaluate the neural plate border genes based on in situ hybridization. Pax3 was unchanged, although there was a change seen by RNA seq. The in situ studies suggest that the neural plate is intact. For this resubmission, we treated embryos with CAPE at shield stage, and studied neural plate border markers by in situ, and there was no major effect on early neural plate development (see comments to reviewer 3).

> While addressing cell death and proliferations the authors quantified effects over region when they have the opportunity to specifically address changes over GFP+ neural crest. While the authors suggest that the dramatic effects in cell death arise late, it seems relevant that the cell death increased at 10µM CAPE, the same concentration used through several other experiments.

We agree with the reviewer that cell death is an important consideration for evaluating the mechanism of CAPE since it inhibits Akt signaling. While we did see cell death at 24 hpf with 10 μM CAPE treatment, we used 5 μM CAPE for most experiments beyond 17 ss to reduce developmental defects in the embryos. At this concentration we did not see a substantial increase in cell death up to 48 hpf, but we still saw dramatic changes in mitf and crestin:EGFP expression, indicating that cell death is not responsible for the primary effect of CAPE ([Figure 2D](#fig2){ref-type="fig"}, [Figure 2---figure supplement 3F](#fig2s3){ref-type="fig"}, [Figure 3D](#fig3){ref-type="fig"}).

> The pathway analysis results regarding signaling ligands are not very informative in their current format due to over and under expression of the same pathways. And would suggest to remove this portion.

We have revised the ligand section substantially and hope the reviewer feels that it is adequate explained. Reviewer 3 actually had the opposite request, and asked for more clarifications. We will abide by the editor's thoughts, but would like to include this information.

> The Materials and methods section reports that embryonic cell cultures medium contains 12% FBS and N2 (Insulin 5µg/ml), however they do not provide any arguments or considerations regarding these components while addressing the effect of specific signals at multiple points. Did they remove the N2 while addressing FGF2 or Insulin? Certainly FBS has potential interfering components that should have been noted.

It is indeed surprising that growth factor stimulation has such dramatic effects on cell signaling when a high percentage of FBS is included. However it is perhaps less surprising given that specific growth factors were required for neural crest induction in vitro. We found that FGF and insulin still had major effects on the Akt and Erk pathways on top of the FBS treatment. There are essential components to the FBS necessary for neural crest induction, since it does not occur in the absence of FBS. We have included this in the text. We did remove the N2 for the short time period western experiments in [Figure 6](#fig6){ref-type="fig"} since N2 contains insulin and have included this in the Materials and methods.

> It might be relevant to test if other AKT inhibitors (Pi-103 [Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}) could inhibit pAKT triggered by Insulin, FGF2 and iMEK.

We have included additional analysis of the activity of PI-103 under different conditions in [Figure 6---figure supplement 1B,C](#fig6s1){ref-type="fig"}. We found that PI-103 could inhibit p- Akt triggered by Mek inhibition.

> The ERK-PI3K analyses were done in zebrafish cell cultures and report broad activity and effects of molecules on signaling. They may not represent signaling effects mediated by NC.

Though the signaling experiments were done on whole embryo cultures, we were able to correlate the signaling changes in whole embryo cultures with crestin:EGFP expression after one day in culture. We cannot be sure that all cells respond in the same manner to growth factors, but based on the dramatic changes in signaling, it is likely the majority of cells.

> Regarding the model provided in [Figure 6](#fig6){ref-type="fig"} panel E, while ERK activation might block PIP3, this is context dependent. In the experiments here addressed, it seems that ERK inhibition does boost pPI3K, however under Insulin FGF2 activity, robust pERK does not seem to reduce pAKT, and thus the solid line of inhibition between Erk and PI3P might be misleading.

Based on new data we have revised our model as indicated in [Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}. This new model no longer presents the issue pointed out here. The new model has FGF activating both PI3K/Akt and Mek/Erk, but Mek/Erk inhibits PI3K/Akt, and the net result is no change in p-Akt. This model explains why Mek/Erk stimulation by FGF does not reduce p-Akt.

> Reviewer \#3:
>
> The authors have carried out a chemical screen to identify compounds that reduce expression crestin:gfp in a mixed culture of primary cell derived from dissociated transgenic zebrafish embryos. They focus on one compound, CAPE, and find that it reduces expression of neural crest markers in zebrafish, a few hours before leading to widespread cell death. They provide evidence that CAPE acts upstream of phospho-Akt, a well-known regulator of cell viability.
>
> Mechanistic insight from the manuscript is very limited. I would like to see more depth at one level or another. For instance, it is unclear where CAPE acts. The authors mention a paper in which CAPE was shown to inhibit PI3K activity. Is this the authors\' preferred model for the principal locus of control of CAPE in the control of gene expression in NC? If so, why does it depend on FGF signaling? The proposed requirement for FGF signaling is not entirely convincing with the data shown. [Figure 6](#fig6){ref-type="fig"} is rather baffling. CAPE is said to be ineffective in the absence of FGF. But even in the absence of added FGF there must be some basal level of RAS/RAF/ERK/MEK signaling, because addition of a MEK inhibitor massively up regulates the amount of phospho-AKT. The bar chart suggests there is some effect of CAPE, but it does not reach significance. Does constitutively active PI3K rescue the effects of CAPE? This seems unlikely because CA-Akt only partially does so, and loss of pten LOF does not seem to do so. \[As an aside, the pten mutant data is buried and is under-explained ([Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}). Comparing [Figure 6---figure supplement 1](#fig6s1){ref-type="fig"},to [Figure 3E](#fig3){ref-type="fig"} makes is appear that ptena -/-; ptenb +/- have an elevated level of crestin in comparison to wild-types. Is that true? Do the double mutants have other phenotypes accompanying the elevated crestin?\] Returning to the question of the locus of CAPE activity, does CAPE work to reduce p-AKt levels in ptena/b double mutants? Do the PI3K inhibitors work to rescue elevate crestin in such double mutants? If not, then perhaps PI3K really is the central locus of control. There is more to learn from this mutant that would help point to the locus of CAPE action.

This paragraph deals with a number of issues, and we thank the reviewer for pointing these out.

1\) We have modified our model of how CAPE acts to inhibit Akt signaling. CAPE likely acts downstream of FGF stimulation as indicated in [Figure 6---figure supplement 1D](#fig6s1){ref-type="fig"}. This model is consistent with all of our data, including the new data in [Figure 6---figure supplement 1A-C](#fig6s1){ref-type="fig"}.

2\) Regarding the pten mutant data, when we added the second replicate of this experiment to increase the n number ([Figure 6---figure supplement 1E](#fig6s1){ref-type="fig"}) we saw that there is no significant difference in crestin expression between the wild type and pten mutant embryos.

> Another option for mechanistic insight that would elevate the significance of the study would be to dig deeper into the transcriptional regulation. What causes the chromatin to close at the MITF promoter? As the authors noted, Β-catenin is regulated by AKT, and loss of β-catenin activity potentially explains many of the phenotypes described here. The authors show that forced expression of sox10 no longer elevates crestin expression in CAPE-treated embryos and claim that CAPE controls Sox10 activity. However, they provide no evidence for specificity. Would forced expression of another master regulator be similarly disempowered by CAPE expression? The ATAC-seq data is an interesting start, but the authors do not go anywhere with it. By what mechanism does the MITF promoter, but not the PDGFR promoter, become closed upon CAPE treatment? The fact that Sox10 binds both promoters indicates that Sox10 is not likely to be part of the differential effect. What happens to the promoter of Tyrosinase? The authors should probably cite an earlier study showing that 1 μm CAPE, which had no effect on p-AKT, altered the binding of MITF to the Tyrosinase promoter (J Nat Prod. 2013 Aug 23;76(8):1399-405.)

Though the ATAC-seq data was useful in providing a clue to relevant transcription factors for CAPE's activity, changes in chromatin accessibility were likely not the primary mechanism by which CAPE works. We have modified [Figure 4](#fig4){ref-type="fig"} to more clearly indicate this. We show that there was no change in ATAC-seq signal at the crestin promoter, though crestin expression was clearly decreased. We also did not see a reproducible change on the tyr promoter:

Chromatin closing at the mitfa promoter could be secondary to other transcriptional effects of CAPE.

We have added a reference in the Discussion to the J. Nat. Prod. paper mentioned.

We did not find any difference in β catenin phosphorylation (S552) or level with CAPE treatment, so that likely does not explain the effects of CAPE:

We agree with the reviewer that another transcription factor was needed to show specificity for CAPE affecting sox10 activity. We have added the effect of tfap2c RNA injection on crestin:EGFP expression ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). Though tfap2c does not have as dramatic of an effect on crestin:EGFP expression as sox10, we found that it could increase crestin:EGFP expression in CAPE-treated embryos, unlike sox10.

> It appears that some markers, e.g., crestin, are globally in NCN while others, e.g. dlx2a and snai1b, are lost just regionally. Is the region where gene expression is lost the same for all markers with regional loss? What is the relationship of time-of-initiation-of-gene-expression and sensitivity to inhibition by CAPE? Is it as simple as CAPE extinguishes all new gene expression? For instance, if CAPE is applied at shield stage, is induction of the neural plate border markers suppressed? If this is the case, then it is misleading to present CAPE as an inhibitor of neural crest induction.

To confirm that CAPE does not simply prevent new gene expression, we did an additional experiment. We treated embryos with CAPE at shield stage and evaluated neural plate border marker expression at 2 ss (Author response image 4). We found that while 10 μM CAPE was toxic to embryos at this stage, 5 μM CAPE did not change expression levels of pax3a and dlx3b and only slightly decreased anterior levels of msx1b. In contrast, we saw a dramatic reduction in crestin:EGFP, mitfa, and pigment cell gene expression with 5 μM CAPE treatment. Therefore it is unlikely that CAPE simply prevents new gene expression. We have adjusted the main Results section that CAPE's effect on gene expression was restricted to markers of premigratory/migratory neural crest and not those that are expressed earlier at the neural plate border, at least of the genes we tested.

> Related to the previous point, a highly relevant study (Pegoraro et al., 2015), oddly not mentioned by the authors but easily discovered through a Pubmed search on \"neural crest AKT\", it was shown that knockdown of PFKFB4 results in loss of all new gene expression within dorsal embryo, i.e., the domain in which PFKFB4 is expressed, concomitant with loss of p-Akt; all such expression was restored by over-expression of constitutively active Akt. This suggests that the CAPE by reducing p-Akt is a general suppressor of new gene expression, possibly as a consequence of activation (but not completion) of a cell death pathway. The current study offers less mechanistic insight than this previously published work.

We agree with the reviewer that this article is highly relevant to our study and have added a discussion of it to the manuscript. The effect of CAPE that we observed was distinct from that observed by Pegoraro et al. with PFKFB4 loss. Pegoraro focused on the effect of Akt signaling on the early specification of dorsal ectoderm derivatives, while we saw that CAPE affected differentiation of neural crest derivatives. We observed effects on genes downstream of sox10 such as crestin and mitfa, but little to no change in most premigratory neural crest markers (snai1b, foxd3, pax3a, tfap2a, tfap2c) or the neural marker *Sox2*. This would most certainly not be the case if CAPE prevented specification of dorsal ectoderm derivatives. Normal neural crest specification was also indicated by the indistinguishable pattern and levels of sox10:GFP in control and CAPE-treated embryos prior to neural crest migration. Pegoraro et al., on the other hand, saw a failure of neural crest specification as indicated by absence of sox10 and snai2.

Both our study and that of Pegoraro show that Akt promotes cellular differentiation independently of cell death but in different developmental contexts. A comparison of the two studies suggests that there are species-specific differences in the role of Akt in ectoderm development between zebrafish and frogs. We have added these points to the Discussion. We have also changed the wording of the manuscript to indicate that the novel role of Akt is in neural crest differentiation.

As mentioned previously, CAPE did not alter expression of neural plate border markers even when embryos were treated at shield stage.

> It seems plausible that CAPE is simply toxic, by virtue of inhibiting of PI3K and Akt pathways, resulting in reduced gene expression on the way to cell death. In the Pegoraro paper they argue against the possibility by showing that apoptosis could be uncoupled from the defects in gene expression (i.e., by over expression of BCl^-^Xl), but even such an experiment does not rule out the possibility that loss of gene expression results from initiation, but not completion, of an apoptosis program.

While it is certainly a concern that inhibition of Akt could lead to non-specific effects related to cell death, we note that 5 μM CAPE still dramatically reduced crestin:EGFP, mitfa, and pigment cell gene expression while having little effect on cell death up to 48 hpf. Therefore, early effects of cell death are likely not responsible for the effect of CAPE on neural crest gene expression.
